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Abstract 
Purpose. We investigated the incidence and extent of aneurysm growth after endovascular aneurysm 
sealing (EVAS) of abdominal aortic aneurysms (AAA), its relationship with stent movement and 
adherence to the instructions for use of the Nellix endograft.  
Methods. In this retrospective single centre study, we reviewed clinical data and follow-up computed 
tomography (CT) images of patients undergoing elective infra-renal EVAS performed as a primary 
interventions and with a minimum follow-up of 1 year. The baseline postoperative CT scan at one 
month and the subsequent scans were used to measure the maximum AAA diameter, AAA volumes 
and the distance between the proximal end of stents and a reference vessel. AAA growth was defined 
as a change of ≥5mm in maximal AAA diameter and/or an increase of more than 5% in AAA volume. 
Device migration was based on the SVS definition of >10mm downward movement of either Nellix 
stent in the proximal landing zone; furthermore, we defined proximal displacement a downward 
movement of ≥4mm. Patients were categorised according to adherence to the old (2013) or new 
(2016) Nellix IFU.  
Results. 76 patients were eligible for inclusion in our study. Over a 4-year period, diameter change of 
≥5mm was observed in 18 patients (24%) whilst significant volume increase was observed in 50 
patients (66%). AAA growth was not associated with adherence to IFU. Proximal displacement 
occurred in 42 patients (55%) and migration in 16 patients (21%), with similar incidence in right and 
left stents. Proximal displacement was significantly more frequent among patients whose anatomy 
did not conform to the current IFU (p=0.025). AAA growth by diameter increase, was significantly 
associated with both migration and proximal displacement (p=0.000 and p=0.007, respectively). AAA 
growth by volume increase was not associated with stent movement.  
Conclusion. Infrarenal EVAS is prone to AAA growth, irrespective of IFU. The Nellix endoprosthesis may 
also be complicated by proximal displacement and migration, particularly when performed outside 
IFU. AAA growth is associated with stent movement, however it is unclear which is the cause and 
which is the effect. 
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Chapter 1: The Abdominal Aortic Aneurysm 
1.1. Abdominal aorta  
The abdominal aorta is the largest artery in the abdomen and is the continuation of the descending 
thoracic aorta. It is approximately 13 cm in length; it begins at the aortic hiatus of the diaphragm at 
the level of the twelfth thoracic vertebra and ends at the body of the fourth lumbar vertebrae (L4), 
where it divides into the right and left common iliac arteries.1, 2 It is located at the posterior 
abdominal wall in the retroperitoneal space. The abdominal aorta is subdivided into: 
suprarenal/paravisceral segment which is inferior to the diaphragm but superior to the renal 
arteries; and the infrarenal segment which is inferior to the renal arteries but superior to the iliac 
bifurcation. It supplies all abdominal organs, the pelvis and lower limbs with its terminal branches. 
The mean calibre of the abdominal aorta diminishes in size from proximal to distal end as a result of 
the large vessels that branch off it; the extent of this escalates with advancing age.3 The curvature of 
this vessel is described as convex as it follows the bodies of the lumbar vertebra to the left of the 
inferior vena cava, with the peak of this convexity corresponding to the level of the third lumbar 
vertebra.4  The aortic bifurcation is usually found at L4 and the angle of bifurcation is variable.5 
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1.1.1. Abdominal Aortic Diameters 
Steinberg and Stein first measured normal abdominal aortic diameters in 1965 using intravenous 
aortography.6 They presented diameters at different levels for both sexes, from the level of the 11th 
rib to the aortic bifurcation. The range was 18.7-26.9mm in men and 17.5-24.4mm in women, with 
the largest value at the most proximal point and evidence of tapering as the vessel progresses 
towards the bifurcation. They also reported that increasing age is associated with increasing 
diameter, particularly after the age of 60.7 It is well established that, between the ages of 25 to 70 
years, the abdominal aorta (AA) increases in diameter by at least 25%.8, 9 As well as age, there is a 
positive correlation between height and diameter.10 Normal aortic diameters are associated with 
gender, with wider vessels in males.9  The mean maximum adult infrarenal aortic diameter 
measured by computed tomography (CT) is 19-21mm in men and 16-18 mm in women.11 There is 
evidence of ethnic variation of diameters found in the literature. 12-15 Needleman et al presented 
diameters collected using ultrasound which equated to a comparable 20 mm in men and 17 mm in 
women (SD 2.5 and 1.5 respectively).3 
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1.1.2. Aortic wall 
The physiological aorta is profoundly elastic in nature and its wall is made of three layers, from the 
innermost: tunica intima, tunica media and tunica adventitia. The tunica intima is made of a single 
layer of endothelial cells supported by elastin-rich collagenous tissue. This is followed by the sub-
endothelial tissue which consists of myo-intimal cells dispersed within it; these cells are comparable 
in composition to smooth muscle cells. Lipids can accumulate here and atheroma can arise within 
this layer. The tunica media is made of concentric sheets of elastin, collagen and a small number of 
smooth muscle cells. The tunica media is the layer that undergoes the most prominent changes in 
aneurysmal disease, with denser collagen fibres making the wall thicker and less pliable. The 
outermost tunica adventitia comprises of collagen with diffusely distributed elastin fibres.16  
Collagen and elastin play vital mechanical roles in the aorta. Collagen expands by a limited 
percentage of 4% of its original state and it grants the aorta tensile strength to prevent over-
distension, especially at high pressure. Elastin is able to expand by 50-70% of its original length and 
enables an even distribution of stress in the wall.17 At low pressures elastin bears most of the 
stress/pressure load on the aortic wall maintaining the equilibrium between mural haemodynamic 
stress and the resultant deformation.  
Differences in the physiological mean thickness of the aortic wall have been identified, within 
different groups of age, gender and ethnicity.18 Thickness of the different layers of the AA within 
normal subjects have not been studied extensively with normal values not well established.19 
Restrepo et al microscopically measured the intima wall thickness of 2472 healthy subjects aged 15-
64 which were 0.10 mm for men and 0.09 mm for women.20 Astrand et al reported a mean intima 
media thickness of 0.73 mm (SD = 0.15) for men and 0.73 mm (SD = 0.16) for women using B-mode 
ultrasonography.21 Arthur et al assessed aortic wall thickness using magnetic resonance imagining 
(MRI) in subclinical cases. MRI identified that men had significantly greater mean wall thickness (2.32 
vs 2.11 mm, p = 0.028) and maximal wall thickness (3.85 vs 3.31 mm, p = 0.010) than women.19 
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1.1.3. Relations2 
The AA is covered, anteriorly, by the lesser omentum and the stomach, behind which are the 
branches of the celiac artery and the celiac plexus; below these, by the splenic vein, the pancreas, 
the left renal vein, the inferior part of the duodenum, the mesentery, and aortic 
plexus. Posteriorly, it is separated from the lumbar vertebra and intervertebral fibrocartilages by the 
anterior longitudinal ligament and left lumbar veins. On the left side the left ceoliac ganglion, the 
ascending part of the duodenum and portions of the small intestine can be found. On the right 
side it is in relation above with the azygos vein, cisterna chyli, thoracic duct, and the right crus of the 
diaphragm—the last separating it from the upper part of the inferior vena cava, and from the right 
ceoliac ganglion; the inferior vena cava is in contact with the aorta below. On the left side are the 
left crus of the diaphragm, the left ceoliac ganglion, the ascending part of the duodenum, and some 
coils of the small intestine. 
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1.1.4. Branches  
The branches of the descending aorta are described as arising and coursing in three main ‘vascular 
planes’: 
1. Posterolateral: paired parietal 
2. Anterior midline: unpaired visceral  
3. Lateral: paired visceral  
Paired parietal branches of the aorta supply blood to the diaphragm, posterior abdominal wall 
vertebral column, vertebral canal and its contents.3, 22  The anterior midline visceral plane first gives 
off the ceoliac trunk immediately below the diaphragmatic hiatus. One cm below the origin of the 
coeliac trunk, the superior mesenteric artery (SMA) originates at the level of the 1st to 2nd lumbar 
intervertebral discs (L1-L2).  The inferior mesenteric artery (IMA) branches off from the anterior or 
left anterolateral aspect of the AA, approximately 3 cm above the aortic bifurcation at the level of 3rd 
Lumbar vertebrae disk (L3). The paired renal arteries just below the SMA with the right branch 
originating slightly higher. Inferior to the renal arteries is where the gonadal arteries originate. The 
median sacral artery, an unpaired branch, may be said to occupy a forth (posterior) plane because it 
arises from the posterior aspect of the aorta, just above the aortic bifurcation.23 There is well 
established evidence of a vast variation in the morphology of the AA and its branches which occur at 
the early stages during embryological development24-26  
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1.2. Abdominal Aortic Aneurysm  
1.2.1. Definition  
The term aneurysm is derived from the ancient Greek and means ‘a widening’. It is defined as a 
permanent localized arterial dilation of at least 50% of what is deemed normal and involving all 
three layers of the artery.27 Pseudo-aneurysms, also known as false aneurysms, occur when the 
widening does not involve all three layers of the artery; they form as a result of a rupture of the 
arterial wall and formation of a perivascular haematoma.28  
Abdominal aortic aneurysm (AAA) is a condition in which the abdominal segment of the aorta below 
the diaphragm becomes weakened and balloons outwards. Aneurysmal dilatation of the aorta is 
commonly found below the renal arteries.29 However, expansion can also be found in the suprarenal 
segment, can extend upwards into the thoracic segment of the aorta above the diaphragm and 
downwards beyond the aortic bifurcation into the common iliac arteries.30, 31 
Various recommendations regarding what constitutes an AAA  have previously been published;32, 33 a 
widely used diameter threshold is 30mm.34 Due to the known physiological variation between 
different groups, as previously described, this has been challenged by some who suggest that an 
individualised comparison of the maximum diameter to the proximal segment should be 
considered.35, 36 The Society of Vascular surgery (SVS) recommends the use of multifactorial 
evaluation: site, aetiology and clinical-pathological manifestations.36  
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1.2.2. Epidemiology  
AAA predominately manifest in men aged 65 or over, with prevalence in this cohort ranging from 
4.5% to 7.7%.37-42 Age has been reported to be the strongest risk factor, with the prevalence rising 
from 2.6% to 9% between ages 60-64 years and >75 years in men.43 Women are 3-4 times less likely 
to develop this disease,44, 45 however, when diagnosed, they have higher rupture, growth and 
operative mortality rates when compared to men.44, 46-49 The reasons behind the difference in 
incidence between the genders is not well understood, but is thought to stem from the same 
physiological mechanisms that govern the lower rate of atherosclerotic disease in premenopausal 
women.50 Epidemiological differences between different ethnicities also exist, with Caucasian groups 
expressing the highest levels of AAA and the Asian population the lowest.51, 52  
The incidence of AAA presentation in England and Wales increased until the late 1980s but has since 
declined.53, 54 This decline is thought to be due to a changing epidemiology,54 with this alteration 
attributed to public health campaigns as a primary prevention and better management of 
contributing diseases such as hypertension and hypercholesterolaemia.55 56 Other studies 
corroborate with these findings.15, 56, 57 
Each year in England and Wales, AAAs cause over 4000 deaths following aortic rupture,58 with 
approximately 8000 patients a year undergoing surgery to prevent this.59 However. The age-
standardized AAA mortality rates have recently been reported to decline by 5.03% every year, this is 
thought to be as a consequence of the screening programme introduction.60 
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Smoking and other risk factors  
Smoking is possibly the strongest environmental factor linked with the incidence and prognosis of 
the disease, with this association being stronger than that between smoking and cardiovascular 
disease.61-65 The odds of a smoker having an AAA of 4 cm or greater, when compared to a non-
smoker are as high as 5.57 [95% confidence interval (CI) 4.24 to 7.31].66 Additionally, smoking has 
been found to escalate the progression of the disease and with that the rupture rate.67 Other studies 
have shown that there is a significant association of disease progression with the duration of 
smoking exposure and the time since smoking cessation.62 Lederle et al identified that cigarette 
consumption in American adults was proportionate to the decrease in deaths from ruptured AAA 
(Figure 1.1).58   
 
Figure 1. 1 Cigarette consumption and age-adjusted AAA deaths per 100000 white men per year in 
the United States.58 
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Other potential risk factors include increased height, hypertension, high cholesterol, and decreased 
lung function. However, these associations are inconsistent within the literature.66, 68, 69 Diabetes 
mellitus has been found to decrease the incidence of AAAs,66, 70 and this is especially notable 
considering that the prevalence of diabetes is higher in the Asian population relative to the 
Caucasian population.71 Additionally, diabetes has been linked with slower AAA growth rate.67 
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1.2.3. Detection, screening and surveillance  
There are many different screening methods for AAA, of these, B-mode ultrasonography is 
widely accepted as the standard, as it presents a high level of sensitivity (94% to 100%) and 
specificity (98% to 100%).72-77 It is non-invasive, inexpensive and does not expose the patient to 
any radiation. Although CT is also highly sensitive and specific as a screening modality for AAAs, 
it is not used as a first line option as it exposes the screened individual to radiation and is 
comparatively expensive.73, 78  It is noteworthy, that whilst there is a significant correlation 
between diameters measured by either method, there is also a certain variability.79, 80 
The UK National Health service AAA screening programme (NAAASP) completed its launch in 2013.81 
Its introduction was based on the results of the multicentre aneurysm screening study (MASS) and 
the Danish Virborg trial.38, 82, 83 These studies showed that a single ultrasonography appointment at 
the age of 65 years resulted in a reduction in AAA related mortality. AAA screening remains cost 
effective to a prevalence of 0.5%.84 Results of the screening programme are promising.85, 86  
In the United Kingdom (UK), between 2015 and 2016, 2549 men were diagnosed with AAAs of 
227,543 screened (1.1%).  However, only 723 of them (0.3%) had AAAs large enough (at least 55 
mm) to require referral for surgical consideration.87 Many subjects with screen-detected AAAs do 
not require immediate treatment and are therefore enrolled into ongoing surveillance.88  
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1.2.4. Medical therapy  
Numerous medical therapies for the prevention and treatment of AAA have been proposed, 
however, the evidence behind these has been insufficient and inconsistent.  Anti-hypertensive 
therapy has been evaluated, as hypertension was found to be strongly associated with the disease.89 
Beta-blockers were amongst the first to be assessed, initially with encouraging results,90, 91 which did 
not translate convincingly when tested on the affected population.92 Angiotensin converting enzyme 
(ACE) inhibitors were also studied,93-95 however AAA rupture and growth rate have not been shown 
to reduce with their use.89, 96 Other evidence points towards this treatment having a harmful 
effect.97, 98 Non-steroidal anti-inflammatory drugs (NSAIDS) have been linked with reduced AAA 
growth,99 however this finding is inconsistent in the literature.100 
Trials have investigated the impact of antibiotics on the progression of AAA. Although there have 
been some encouraging results on small samples, larger studies are needed to confirm any 
benefit.101-103 
The most promising evidence for the potential treatment or decreased progression of AAA is 
perhaps that on statins.100, 104 The mechanism by which this occurs is unknown, especially since high 
levels of lipids have not been linked with AAA.67, 105 One study, which set out to investigate this trend 
further, was closed pre-maturely due to the low number of participants.106 It was also deemed 
unfeasible and unethical to conduct randomised control trials (RCTs) on a population with many 
subjects having an independent indication to statin therapy, as the comparative group would need 
to be statin-free.  
A recent systematic review and meta-analysis investigating the impact of various medical therapies 
on growth rates of AAA demonstrated little evidence for reduction in growth rates across a range of 
pharmaceutical products, but supported statins as the only therapy to show encouraging results, 
with a pooled difference in growth rate of –2.97mm/year (95% CI –5.83 to –0.11mm/year) between 
patients prescribed statins and control.107  
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1.2.5. Open surgical repair  
Dubost et al published the first case of open repair of AAA in 1952.108 During open repair, the AAA is 
exposed using a transperitoneal or retroperitoneal approach, a clamp is placed on the aorta above 
the AAA, which is then opened and a graft made of synthetic material, usually Dacron, sutured into 
place. The extent of arterial replacement is dependent on the extent of aneurysmal disease. In most 
cases, a single graft tube is sutured into place, however with moderate to severe dilation at iliac 
system a bifurcated graft is inserted beyond the aortic bifurcation. On completion of the repair, the 
AAA is loosely closed over the newly inserted graft.  
This is a major operation and bears a significant risk of operative mortality and morbidity. Elective 
open repair results in better outcomes when compared to emergency repair, which has mortality 
rates of 30% -60%.109-111  The UK National Vascular Registry Report of 2017 reported a mortality rate 
of 2.9%,112 whilst the US Aneurysm Detection And Management (ADAM) trial reported a mortality of 
2.7%.113 National outcomes of 30-day operative mortality in the United Kingdom were as high as 
12% in district hospitals.114 It has been suggested that complications of open AAA repair are under-
reported; Medicare data in the USA showed complication rates up to 10% at 4 years.115 However, 
late complications are still thought to be infrequent and long term follow-up is not felt to be 
necessary.  
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1.2.6. Endovascular aneurysm repair  
In 1991, both Parodi et al in Argentina and Volodos et al in Ukraine were the first to describe elective 
endovascular aneurysm repair (EVAR) of AAAs.116, 117 EVAR was a revolutionary breakthrough for AAA 
therapy as it moved away from the major open surgical approach and marked the start of the 
evolution of the more refined endovascular therapy available to patients today.118 This evolution 
was made possible with advances in patient selection, implantation technique and endoprosthesis 
design.119 In 1994 the first EVAR procedure in an emergency setting was described,120 with EVAR now 
resulting in lower mortality when compared to open repair.121-127  
EVAR has surpassed open repair as the most common technique for treatment of AAA.128 Despite 
this, anatomical constraints still exist and not all patients can be treated with commercially available 
infra-renal devices. Establishing suitability for EVAR is a complex process and is dependent on 
manufactures instructions for use and the surgeon’s clinical judgement. The current literature 
presents varying degree of suitability of EVAR, ranging from 25% to 75%.129-135 Fenestrated and 
branched graft designs have recently emerged to treat more complex and challenging anatomy with 
promising early results, but these grafts are expensive and require complex implantation 
procedures, with higher mortality and morbidity when compared with standard infra-renal EVAR.136-
140  
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The procedure 
EVAR has become less invasive over the years, as it is now most commonly performed using a fully 
percutaneous approach, where previously small incisions in each groin were needed to expose the 
femoral arteries for device deployment.  Intra-operative fluoroscopy provides visual information on 
the location of the graft throughout its journey to the AAA and during implantation. The graft is 
positioned in the correct place using guidewires and catheters. This does expose the patient to 
relatively high doses of radiation and infra-arterial contrast agents which are not needed during 
open surgical repair.   
EVAR stents are anchored to normal arterial segments both proximally (infra-renal aortic neck) and 
rely on radial force in the iliac arteries for seal and fixation. This is made possible by two main 
mechanisms: the first is through the use of hooks or barbs; the second is the radial force exerted by 
oversized self-expanding sealing stents at the landing zones (Figure 1.2). To ensure a stabilised 
device, fixation must overcome distraction forces generated by the inflowing circulation.  
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Figure 1. 2 Endovascular Aneurysm Repair 
 
(A) Unsheathing of the stent after optimal positioning within the AAA, using catheters 
(B)  Visual representation of the EVAR device after competition of implantation 
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EVAR outcomes 
Mortality rates post-EVAR is lower than with open repair, and is reported at 0.4% in 2017.112 
Furthermore, patients have an overall shorter hospital stay following EVAR.132 EVAR is less than 30 
years old; there is thus a  degree of uncertainty regarding the long-term durability of the grafts; late 
complications appear to be more frequent than after open repair.141  The EVAR 1 trial has shown 
that the long-term outcome of EVAR may be inferior to that of open surgery,142 a real concern due to 
the rapidly growing life expectancy in the western world. Most clinicians will thus follow-up patients 
indefinitely post-EVAR. Surveillance imaging modalities include duplex ultrasonography, plain 
radiography and CT.143, 144 The problem of late failure of EVAR has not been satisfactorily addressed 
so far, and is partly responsible for the comparatively high costs of the technique.145 (Detailed rates 
of complications bellow) 
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Chapter 2: Endograft related Complications  
2.1. Endoleaks and endotension  
2.1.1. Definitions 
White et al first proposed the concept of endoleak in 1996.146 He defined endoleaks as blood flow 
outside the lumen of the endoluminal graft, but within the AAA.147 Endoleaks arise due to 
incomplete exclusion of the AAA from the circulation. Some of the causes include: incomplete seal 
between the endograft and the wall of the blood vessel, an inadequate connection between 
components of a modular endograft, fabric defects or porosity, or retrograde blood flow from 
patent aortic side branches.147, 148  EVAR has been reported to be complicated by endoleaks in up to 
25% of cases.149-151  
2.1.2. Classification of endoleaks 
2.1.2.1. Timing147  
When an endoleak occurs during the 30-day postoperative period, it is defined as a primary 
endoleak; detection beyond 30-days implies a secondary endoleak.  When an endoleak re-appears 
after resolution (spontaneous or with help of intervention) it is known as a recurrent endoleak. 
2.1.2.2. Type I endoleak  
A type I endoleak develops due to an incomplete seal at the proximal aortic attachment site (type 
IA), at the distal iliac attachment site (type IB) or at the site of an iliac occlude, in patients treated 
with aorto-uni-illiac endografts (type IC). Short, severely angulated, reverse tapered, calcified and 
diseased necks are more prone to type IA endoleaks. Neck morphology has also been shown to 
predict this type IA endoleak, with evidence suggesting a neck diameter of > 28 mm significantly 
increases its incidence.152 Type I endoleaks imply a persistent or recurrent risk of rupture, as the AAA 
remains exposed to systemic arterial pressure.153-155 
Although small intra-operative type I endoleaks may resolve spontaneously, the SVS recommends 
that, if identified intraoperatively, surgeons should make every attempt to treat them prior to 
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procedure competition. This is commonly done using balloon moulding of the proximal seal zone, 
proximal extension cuffs or endostaples.156 The latter has also been reported to reduce the risk of 
stent migration (see below).156, 157 Specific treatment for type IA endoleaks also include embolization 
with coils or glue,158, 159 proximal extension with visceral chimneys (ChEVAR),160 and using 
fenestrated endovascular aneurysm repair (FEVAR).161 ChEVAR and FEVAR allow the proximal seal 
zone of the stent to extend above the renal arteries, whilst preserving the flow into the renal 
arteries. Type IB endoleaks may be treated with distal extensions.162, 163Conversion to open repair 
may be necessary in patients with persistent type IA endoleak.136  
2.1.2.3. Type II endoleak 
Type II endoleak is attributed to retrograde flow from AAA side branches such as the lumbar arteries 
or IMA.164-166 This is the most common endoleak, present at the time of repair in up to 25% of cases, 
although more than half will spontaneously resolve.153, 158, 159, 167 At 6 months, 10% to 15% of EVAR 
patients have this type of endoleak.168-170 Important risk factors include number and diameter of 
patent lumbar arteries, a patent IMA and anticoagulation.171-173  
Exclusion of type II endoleaks can be achieved with embolization of the vessel with coils or glue,159 
direct translumbar injection of the AAA sac,174 trans-caval embolization,175, 176 and laparoscopic 
ligation.177 More than half of treated type II endoleaks persist, leading to multiple procedures and 
occasionally open conversion.178, 179 Other treatment options include over-sewing of the affected 
arteries whilst preservation of the stent.180-182  
A type II endoleak may on occasion only be detected 6 months postoperatively or later. These 
endoleaks are particularly associated with AAA growth.183 However, they rarely lead to rupture and 
when they do they are often associated with a type I endoleak. Surgeons anticipate this when there 
is a maximum AAA diameter increase in size by 5 mm or more.184, 185 EVAR AAA growth rates are 
reported to occur in 18.3% of patients.186 
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2.1.2.4. Type III endoleak  
Type III endoleaks usually occur due to a defect in the graft. This can arise due to incomplete seal 
between components and graft separation (IIIa) or due to a hole in the fabric (IIIb).187 This causes re-
pressurisation of the AAA cavity by the systemic pressure, and therefore it bears a significant risk of 
rupture. Treatment is necessary and is dependent on the site and cause of the endoleak.153 
2.1.2.5. Type IV endoleak 
A type IV endoleak is a leak due to fabric porosity. This rarely requires treatment as it seals 
spontaneously.188 Type IV endoleaks are unlikely to occur with modern endografts.  
2.1.2.6. Type V endoleak/Endotension 
Endotension is AAA enlargement without a detectable endoleak. Causes include undetectable 
endoleak due to limited or inadequate imaging modality,155, 189, 190 pressure transmission through 
thrombus or endograft fabric,191-194 or accumulation of a serous ultrafiltrate across a microporous 
fabric.195 It is now well established that AAA can continue to grow after endovascular repair with 
absence of a detectable endoleak.190, 192, 196-198 Type IIIb endoleaks are very difficult to diagnose and 
are thought to be responsible for a portion of cases of endotension. Management is individualized 
and can entail observation, empirical relining of endografts (to treat suspected type IIIb endoleaks) 
or conversion to open repair.  
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2.2. Stent movement 
Different terms have been used to report stent movement for the EVAR device in the literature. In 
2002 the SVS used the term stent migration and defined it as movement of ‘>10mm relative to 
anatomical landmarks or any migration leading to symptoms or requiring therapy’.199 Greenberg et 
al added a definition for device migration as any movement of more than twice the reconstructed 
resolution of the CT scan.200 When deciding between the SVS definition and this definition, 
Greenberg et al suggests that clinicians should choose whichever value is lower.200 Greenberg et al 
accepts the SVS definition and suggested a fixed anatomical landmark which was embraced by the 
vascular community.  
Stent movement can occur at the proximal side or the distal side of the stent. At the proximal end of 
the stent the fixed anatomical landmark was defined as the SMA, whilst at the distal end it was the 
hypogastric artery and the aortic bifurcation. The direction of movement of the stents is categorised 
as cephalic or caudal. Caudal stent movement is determined by a plus sign (e.g. 11mm) and 
movement in a cranial direction is indicated using a minus sign (e.g.-11mm). 
Stent movement occurs most frequently in the caudal direction at the proximal end of the 
endograft. This movement towards the AAA may lead to a type IA endoleak. Cranial stent movement 
at the distal landing zones may arise due to aortic remodelling and can lead to type IB endoleaks. 
Device migration is a late complication with its onset commonly reported 2 years post-
operatively.201-203 EVAR has been reported to be complicated by device migration in 1-10% of 
cases.204-206 Causes of stent migration include incomplete device fixation, an anatomically hostile 
neck and progressive aortic dilation/elongation.201, 207-209 
Management of migration in the caudal direction is dependent on anatomical features such as the 
quality of the aortic neck (seal zone) and aortic neck length. Treatment options include conversion to 
open repair and proximal extension (with or without chimneys or fenestrations).161, 210  
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Figure 2. 1 Endograft migration211  
 
(A) Lateral radiograph 1 month post-EVAR, stents and vertebrae visible; (B) the intraoperative digital 
subtraction angiography at the time of endograft placement; (C) lateral radiograph 2 years post-EVAR - 
endograft limbs are bowed anteriorly suggests marginal movement; (D) the distal ends of the iliac limbs have 
cephalic migration, arrows point at a resultant type Ib endoleak. 
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2.3. Limb occlusion 
One fourth of all arterial reinterventions after open repair are due to limb occlusion.212 Risk factors 
include female gender, grafts extending to the external iliac arteries, associated occlusive disease 
and non-supported limbs.213 Patients typically present with claudication or severe acute ischemia.214, 
215  
The EVAR 1 trial revealed that bifurcated surgical grafts are less likely to occlude vessels than AUI 
endograft devices.141 The incidence of limb occlusion post-EVAR is approximately 4% (median follow-
up 1.7 years (range 0-4.6 years)), with a great proportion presenting by 2 months post-EVAR and 
close to all within the first year.216-218  
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Chapter 3: Endovascular Aneurysm Sealing 
3.1. Device description and implantation procedure  
Endovascular aneurysm sealing  (EVAS), which, presently, can only be performed with the Nellix 
endograft (Endologix Inc., Irvine Ca., USA), is a novel endovascular treatment of AAAs. The endograft 
received Conformité Européenne marking in April 2013 and was subsequently introduced into 
clinical practice.219-221  
Its innovative design is made up of one console and 4 separate components per stent: a 17 Fr 
delivery catheter; a 10mm balloon expandable cobalt-chromium stent; a non-porous 
polytetrafluoroethylene (PTFE) endobag which surrounds the stent and a bio-compatible polymer 
(polyethylene glycol diacrylate hydrogel) which, once injected, is contained within the endobag 
(Figure3.1).  
Bilateral percutaneous or surgical femoral approach is used to allow 0.35 inch guidewires to be 
introduced through each femoral artery and advanced into the thoracic aorta. The Nellix devices, 
one on each side, are then advanced over these guidewires and positioned in the aortic neck. The 
stents, which extend into the common iliac arteries distally, are then unsheathed using the pin and 
pull technique. The console, which is attached to the caudal end of the device, enables simultaneous 
inflation of the balloon expandable stents and the injection of polymer into the endobags at supra-
systolic pressure, which mould to the AAA sac lumen and provide a complete seal proximally and 
distally. As the endobags fill with the polymer, which can be mixed with contrast agent for visibility 
under fluoroscopy, the console monitors filling pressure to a target of 180 to 220 mm-Hg, at which 
the seal is normally achieved. Once the endobags are filled with the polymer liquid it takes under 5 
minutes at 37 degrees Celsius (°C) for the polymer to completely cure and harden to a rubbery 
consistency, sealing the AAA sac. During the curing time, the polymer turns from translucent to 
opaque white. Throughout the procedure, the endoprosthesis is visualised under fluoroscopic 
guidance, with angiography to assess stent position and patency of renal vessels. 
P a g e  | 24 
 
Advances to the EVAS procedure include the introduction of the ‘prefill’ method. Before polymer 
introductions the endobags are filled with saline to the target pressure, to accurately estimate the 
polymer fill volume and to assess device stability during endobag filling. Additionally it allows, if 
needed, the repositioning of the device after prefill aspiration. Contrast can also be added to the 
saline solution to allow visualisation of the endobags.  
Figure 3. 1 EVAS device222 
  
 
 
 
 
 
 
 
 
(A) Animated view of the Nellix device after implantation  
(B) The Nellix console, with view of the pressure monitor  
(C) Animated cross-sectional view of the device within the AAA during polymer filling  
 
 
A 
B
 
C 
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3.2. Device stability 
The sac-anchoring nature of the graft aims to preclude any movement of the stent. Once cured, the 
polymer exerts no radial force on the aortic wall: it stays in place by obliterating all space into which 
it could move, leaving no space within the AAA to be filled by endoleaks. While conventional 
endografts have a proximal and distal attachment zones for fixation, the Nellix endoprosthesis does 
not have any active fixation mechanism (hooks, barbs, radial force). 
EVAS also relies heavily on the assumption that the AAA and the thrombus contained in it do not 
change after implantation. Any such change could result in device displacement, potentially leading 
to endoleak and rupture. Depressurised AAAs treated by EVAR or EVAS should not grow in time, 
hence post-EVAR AAA growth, which is known to occur in a proportion of patients, is taken as a sign 
of failure to exclude the AAA from the systemic circulation. For EVAS patients, a change in the 
volume of the AAA and the thrombus contained in it, may result in movement of the stents, leading, 
potentially, to endoleak and rupture. AAA growth post EVAS has not been widely reported but may 
have worse consequences than those seen in EVAR, given the lack of active fixation by the Nellix 
endoprosthesis and its known reliance on the lack of anatomical change post implantation.  
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3.3. Instructions for use  
Despite the fact that the device had instructions for use (IFU), its adaptable concept, led many 
clinicians, during the early use of the device, to believe that treating patients beyond these 
instructions was in fact possible and safe.223, 224 There was a certain perception that, the use of 
endobags which conform to any anatomy, made Nellix widely suitable. This included AAAs with a 
short or no neck, as the neck was no longer necessary to stop flow in the AAA at the time of 
implantation. However as complications arose this changed.225 The EVAS FORWARD Global Registry 
reported that 37% of patients were in fact treated outside of IFU.226  
Early outcomes dictated a change in the instructions for use (IFU) in October 2016 (Table 3.1),227 
which included modifications aimed specifically at reducing the occurrence of migration and AAA 
enlargement (Figure 3.2).228 The old IFU allowed for a greater morphological applicability than EVAR, 
and with that expanded the proportion of treatable patients with AAA.229 The new IFU removed this 
advantage. 
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Table 3. 1 IFU-2013230 and the modified IFU-2016228 
IFU-2013 IFU-2016 
Iliac and femoral artery access that 
allows for atraumatic device 
introduction 
No Change 
Aortic proximal neck diameter range of 
18 to 32mm 
Aortic proximal neck diameter range of 
18 to 28mm 
Minimum aortic proximal neck length 
of ≥ 10mm 
Criteria remains the same; however, 
the definition of aortic proximal neck 
length is updated to diameter change 
of 10% vs. previous 20% 
Proximal aortic neck angulation of ≤60° No Change 
Aortic aneurysm with a blood lumen 
diameter of ≤70mm 
No Change 
N/A Ratio of maximum aortic aneurysm 
diameter to maximum aortic blood 
lumen diameter <1.4 
Iliac arteries luminal diameter range of 
9 to 35mm 
 Iliac artery blood lumen diameter 
range of 9 to 35mm outside the distal 
seal zone 
 Distal seal zone: length of ≥ 10mm 
and diameter range of 9 to 25mm 
 
 
Figure 3. 2 Refined Nellix IFU228 
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3.4. The challenges 
Van Noort et al showed that precise positioning of the EVAS device in the aortic neck may be 
difficult.231 This study suggests that, despite operator experience, only half of the proximal sealing 
(landing) zone in the aortic neck is used, on average. They recommended that the stent should be 
positioned 5 mm above the lower boundary of the renal arteries instead of below, as the endobags 
often present with shoulders (a rounder rather than flat top almost perpendicular to the axis of the 
stent-graft frame) which causes loss of aortic neck seal (figure 3.3).  This implies that the device, at 
its present used, can produce a tenuous seal in short necks, which may potentially be lost with 
minimal stent movement.  On this basis, if minimal movement of the prosthesis occurs, failure may 
be inevitable. In addition, if the device is used in shorter necks (10mm or more), seal may not be 
achieved at the time of implantation, despite absence of a visible endoleaks. 
 
The post-operative visualisation of type Ia endoleaks after implantation of the Nellix device can be 
difficult as the polymer within the endobags is commonly radio dense, especially during the early 
follow-up period.232 Van den Ham et al set out to classify endoleaks post-EVAS in a multi-centre 
analysis including 1851 patients (median follow-up 1.4 years ± 0.78 years). They acknowledged that 
there is a possibility of AAA pressurisation in the absence of visible endoleaks heralded AAA growth 
(by volume or diameter), thrombus volume growth, new thrombus between the endobags, endobag 
separation or any movement of one or both endobags or stents.233  
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Figure 3. 3 Schematic representation of the Nellix in the infrarenal AA. Example of differences 
between the top of the stent frame and the top of the left endobag (flat shoulder) and right endobag 
(drooping shoulder).231 
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3.5. EVAS outcomes 
Thirty-day outcomes   
Brown et al demonstrated satisfactory early outcomes of EVAS in a recent systematic review of 11 
studies, which included 684 patients.234  30-day mortality rate was 2.6 % in the full cohort and 1% for 
elective patients. At 30-days endoleaks were noted in 4.7% of all patients and 4.8% in elective cases. 
30-day AAA related re-intervention rate was 5.7% and 4.6% in the full cohort and elective patients, 
respectively. These promising early outcomes are consistent within the literature, including the EVAS 
FORWARD Global Registry.226, 235  
 
Mid-term and long term outcomes  
Long term follow-up data is limited within the current literature. Stenson et al recently reported 
midterm results (up to 3 years) of the EVAS devise which included the comparison of the different 
IFU groups.236 Just under 25% of their patient cohort (150 patients) underwent re-intervention, 14 % 
of patients had a type 1 endoleak and secondary rupture was reported in 4.7% of patients. The study 
concluded that when adhering to IFU the device has acceptable results, particularly with respect to 
migration (>5mm).236 Migration was identified in 5.3% of patients. England et al identified migration 
(≥4mm) in 28% of patients at one year.237 Boeckler et al also reported Type Ia (3%), type Ib (2%), and 
type II (2%) endoleaks in a recent multicentre case series (171 patients).238 
 
Argani et al developed a mathematical model that encompasses the forces that act on the sealed 
AAA: both static and dynamic.239 These include Eigen-frequencies which are as a result of the elastic 
properties of the device and may be initiated by external means, such as walking, running and using 
different means of transport etc. This study suggests that static forces and vibrations elicited from 
daily activities may lead to stent movement and, potentially, migration and endoleaks.  
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3.6. EVAS in Liverpool  
Patient management 
EVAS was introduced in our institute in December 2013 under the supervision of our Techniques and 
Medical Devices group (TaMDg), with strict audit and reporting requirements. In our unit, a team of 
clinicians, at a weekly multidisciplinary meeting, reviews images and clinical information of all 
patients with AAAs requiring treatment and recommends a suitable surgical or endovascular 
technique (including EVAS, where appropriate), according to the fitness of the patient, patient’s 
preference, and anatomical features of the AAA. Informed consent was obtained for the procedure; 
this included an understanding that procedural outcomes would be evaluated and reported 
accordingly.  
Pre-operative Plans  
Surgeons use CT scans visualised with advanced software (Carestream Health Inc, Rochester, NY, 
USA) to obtain measurements for operative plans. The AAA is conventionally described in relation to 
of the proximal landing zone, the characteristics of the AAA sac, the distal zone and the vascular 
access. Figure 3.4 is a planning template commonly used for pre-operative endograft planning to 
evaluate morphological features of the AAA. Diameters are designated by ‘D’ and lengths by ‘L’. 
Diameters are measured from outer-wall to outer-wall. The measurements include the most inferior 
diameter at the inferior renal artery (D1), the distal aortic neck at the start of the AAA (D2), the 
aortic bifurcation (D3), the largest AAA sac (maximum AAA diameter) (D4), and the common iliac 
arteries (D5 and D6). The lengths of the aortic neck (L1), the length from the lowest renal artery to 
the aortic bifurcation (L2) and the length of the AAA sac (L3). Also, the length of the distal landing 
zone is described as the distance from the aortic bifurcation to the common iliac artery bifurcation 
(L4 and L5). Minimal diameters should be recorded in the distal landing zone (D7 and D8) and 
external iliac artery access vessels. Neck angulation is the angle between the flow axis of the 
infrarenal neck and the body of the AAA.  
 
P a g e  | 32 
 
Figure 3. 4 Diagram of the planning template showing the measurements needed for appropriate 
pre-operative endograft planning.240 
 
 
 
 
 
 
 
 
 
 
 
 
Summary of dimeters and lengths measured for optimum AAA therapy, Diameters are designated by 
‘D’ and lengths by ‘L’. Diameters are measured from outer-wall to outer-wall. 
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Follow-up imaging protocol 
Our follow-up protocol includes postoperative imaging by abdominal radiography on the first day; 
duplex ultrasound imaging and arterial-phase CT at 1 month; followed by yearly abdominal 
radiographs, duplex scans, and arterial-phase CT, except in patients with significant renal 
impairment and favourable 1-month CT appearances. CT data are reconstructed using the thinnest 
available slice (≤2 mm) before review. 
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Chapter 4: Methodology  
4.1 Aims 
The primary aim of this thesis was to examine the relationship between AAA growth post-EVAS, 
stent movement and different IFU groups. In detail, the aims of this study were: 
1. Establish whether post EVAS AAA growth occurs 
2. Assess the association between AAA growth and stent movement 
3. Assess the relationship between AAA growth, stent movement and compliance with the 
anatomical criteria of the Nellix IFU 
4.2 Null Hypotheses  
The primary null hypothesis was that EVAS treated AAA growth.  
The secondary null hypothesis was that AAA growth is not associated with stent movement and non-
compliance with the anatomical criteria of the Nellix IFU.  
4.3 Overview  
This was a retrospective observational cohort study conducted at the Liverpool Vascular and 
Endovascular service (LiVES) between September 2017 and August 2018. Patients who underwent 
Endovascular AAA sealing were identified within the LIVES database and theatre records, and 
assessed against the inclusion criteria. A pro-forma was created and retrospective data collection 
was conducted using patient notes, an existing database and CT scans for aortic measurements. We 
used the STROBE checklist (Strengthening the reporting of observational studies in epidemiology) to 
present our observational study in this thesis (Appendix 8.1).241  
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4.4 Permissions and Ethical Approval 
This project fell within a programme evaluating EVAS at our institution, therefore, formal ethical 
approval was not required; the study was registered as a service review (Service review number: 
AC04590) 
 
4.5 Study population 
The inclusion criteria were focused on EVAS performed on infra-renal AAA as an elective primary 
intervention. This excluded EVAS performed on ruptured AAAs, relining of previously inserted grafts, 
treatment of engraft failure and AAA in the juxta/suprarenal segments, in order to reduce 
heterogeneity. 
The following eligibility criteria were applied: 
Inclusion criteria: 
1. Infra-renal EVAS  
2. At least 2 postoperative CT scans: baseline at 1 month (≤6 weeks after device implantation) 
and 1 additional CT scan (minimum of 12 months from the initial implantation procedure) 
Exclusion criteria:  
1. Unavailable CT scans  
2. Patients undergoing EVAS extending into the supra-renal segment (with chimneys) 
3. Patients undergoing EVAS as a secondary intervention (after previous aortic AAA surgery) 
4. Patients treated for ruptured AAAs  
 
EVAS patients were identified on the departmental EVAS database which included demographics, 
clinical and procedural information. 
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4.6 Data collection  
4.6.1. Baseline information  
The EVAS database which was prospectively created by the LiVES team immediately following the 
procedure, was accessed and the inclusion criteria applied to select eligible patients and create a 
refined database. This database included information of patient demographics including age and sex; 
and comorbidities including ischemic heart disease (IHD), chronic respiratory disease, diabetes, renal 
impairment and cancer. We also included information about the current and previous smoking 
status of the patient. The American society of anaesthesiologist (ASA) grade was also noted along 
with whether the patient was on any of the following medications: antiplatelet therapy, statins or 
anticoagulants. (Appendix 8.2; Table 8.2) 
4.6.2. Aortic anatomy 
Pre-Operative plans performed by surgeons were used to collect this data, this included neck length, 
neck angulation, neck diameter, neck calcification/thrombus, shape of neck, preoperative maximum 
AAA diameter, maximum aortic lumen diameter, diameter at aortic bifurcation, maximum right 
common iliac artery (CIA) diameter, maximum left CIA diameter, Iliac tortuosity and maximum 
access diameter (Appendix 8.2; Table 8.3). The anatomical data enabled the determination of 
compliance to IFU-2013 and/or the newly refined IFU-2016.  
4.6.3. Operative variables  
All procedural variations were noted, including the implantation of an aorto-uni-iliac (AUI) device, 
using a single non-paired stent to seal the AAA. We also noted the type of anaesthesia used. Any 
unplanned events during surgery and additional procedures, planned or otherwise, were recorded. 
(Appendix 8.2; Table 8.4)  
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4.6.4. Thirty-day and follow-up outcomes  
We noted Intra-operative complications, thirty-day postoperative outcomes and follow-up outcomes 
as listed in Appendix 8.2; Table 8.5. Intraoperative complications were categorised into device failure 
and operative complications. Device failures were directly linked to any defect, existing or arising 
during the procedure, in any part of the EVAS endoprosthesis including the console, endobag or 
stent.  
For both the thirty-day outcomes and the follow-up outcomes we included information on re-
intervention incidence and type. Death during the 30-day period and the follow-up period were 
noted and the cause specified.  
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4.6.5. CT Measurements 
CT measurements can be divided into 3 groups: diameter measurements, volume measurements, 
and stent movement assessment The use of a Picture Archiving and Communications System (PACS) 
on the Carestream software (version 11.4.1.1011; Carestream Health Inc., Rochester, NY, USA) 
enabled the measurement of all these variables. The named author obtained all these 
measurements using the post-operative CT scans at baseline at one month and subsequent yearly 
scans. The exact time difference between EVAS and post-operative scans was recorded, in days. This 
dictated which year group the scan belonged to. (Appendix 8.2; Table 8.6)  
4.6.5.1 Diameter199 
AAA diameter was measured as the maximum cross-section on reconstructed slices perpendicular to 
the main aortic axis from adventitia to adventitia. AAA growth was defined as a change of ≥5mm 
between the 1-month CT and subsequent scans, in accordance to the SVS definition.242  
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4.6.5.2 Volume measurements243  
For volumes, the Carestream ‘lesion livewire segmentation tool’ was used to measure, at each slice 
(2 mm thickness obtained using the multiplanar reconstruction), the cross-sectional area of the AAA, 
starting below the point of the lowest renal artery to the aortic bifurcation. The lowest renal artery 
was identified by visualising a clear gap between the renal artery and the abdominal aortic stem 
(Figure 4.1). The aortic bifurcation was identified as one level (2mm slice) above the separation of 
the two common iliac arteries. Once the external outlines of both these slices was manually drawn, 
the software automatically generated a volume measurement of the accumulated outlines of all 
levels between these slices. Manual adjustments were performed after visual inspection of each 
cross-section, to eliminate imprecisions generated by inaccuracies of the software.244 Volume 
measurements at one month post-EVAS was subtracted from those on follow-up scans to attain 
volume changes. Inter- and intra-observer variability was within 5% and therefore a change of more 
than 5% was deemed significant; this also a definition used by SVS.242, 245 Inter-observer variability 
was assessed between the named author and two other reviewers. 
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Figure 4. 1 Volume measurements upper limit 
 
Two-dimensional oblique axial view of the abdomen, indicating the AA and the renal arteries emerging from it. 
(A) One slice above the limit of AA volume measurement (B) The point at which volume measurement should 
start. Arrows are pointing at the gap expected when identifying the level at which volume measurements 
should start. 
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4.6.5.3. Proximal displacement and migration237  
The built-in ‘vessel analysis’ module of the Carestream software enabled the measurement of stent 
movement.  Each scan was loaded onto a PACS workstation to generate a semi-automated central 
luminal line (CLL) through each stent using the ‘Aorta Protocol’ tool in the vessel analysis software.  
The ‘Aorta Protocol’ made switching from left stent to the right, and vice versa, automated and 
provided a more unified generation of the stent CLL. The CLL of each stent was checked by scrolling 
through all the anatomical planes available, ensuring that it was indeed traveling through the centre 
of the luminal space. Manual corrections were made, if necessary. A two-dimensional oblique axial 
view, perpendicular to the CLL, was used to determine the position of the stent graft against the 
specified reference vessel.  We defined this as the most inferior point of the SMA, where a clear 
separation of this vessel from the aortic wall was visible, seen on the first oblique axial CLL 
reformatted image (Figure 4.2). The distance between this point and the first oblique axial CLL 
reformat that contained at least two stent struts was measured, reducing the probability of 
mistaking calcification for the actual stent graft. Each CLL measurement was compared with the 
same measurement on subsequent scans. Measurement differences between the CT scan at 
1 month and subsequent scans at different points, for the same anatomic location, were used to 
determine whether device movement had occurred. Caudal movement was indicated by a positive 
value and cranial with a negative value. The bias (difference between true stent movement and the 
CT assessment), intra-observer and inter-observer variability when using this method for the 
proximal displacement definition had been previously reported.246  
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Figure 4. 2 Visual representation of the method of stent to SMA distance measurement. 
 
Central luminal line (CLL) images (in blue) with corresponding oblique axial reformats demonstrate the 
technique used to record stent graft position against the superior mesenteric artery (A). (B) stent struts and 
corresponding to the perpendicular line to the CLL named ‘Sten End 1’. (C) the inferior point of the SMA (clear 
gap from aorta), named on the CLL as ‘Sten Start 1’. 
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Stent movement Definitions  
The reporting standards of the SVS define device migration as movement of >10 mm relative to 
anatomical landmarks or any migration leading to symptoms or requiring therapy.242 England et al 
specifically defined stent migration for the EVAS device in a recent study as ≥4mm relative to a 
vascular landmark.246 This cut-off has also been used to define migration in fenestrated endovascular 
grafts.247 Our method included assessing and reporting stent graft movement (≥4 mm), which we 
defined as proximal displacement in this thesis, and migration (>10mm), as defined by the SVS. 
Proximal displacement is stent movement in the caudal direction.  
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4.7. Data Analysis 
SPSS version 22.0 (SPSS, Inc., Chicago, IL, USA) was used to analyse our data. Continuous variables 
were assessed for normality with the Kolmogorov–Smirnov test and presented as mean and 
standard deviation (SD) or median and range, according to the underlying distributions. Paired 
comparisons were performed with a t-test or Mann-Whitney U test, as appropriate. To assess 
agreement of AAA volume and maximum dimeter we correlated these using Pearson correlation. 
Kaplan-Meier survival curves were generated to visualise freedom from AAA growth, proximal 
displacement and migration patterns (separate figures for each these ‘events’). When the standard 
error exceeded 10%, this was highlighted and a reference line added to the curve. The log rank test 
was used to compare AAA growth/proximal displacement/migration rates between different IFU 
groups. The Fisher’s exact test was used to assess the association of AAA growth with stent 
movement.   
A linear mixed model was used to analyse the trend and rate of AAA growth over time and 
associations of AAA growth with potential predictors. Shek et al published a stepwise method for the 
use of this model which we used in this thesis, as recommended by a senior statistician.248  
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Chapter 5: Results  
5.1. Patients 
5.1.1. Selection  
112 consecutive patients (86 men) with a mean (SD) age of 77 (7) years underwent EVAS between 
December 2013 and January 2018. The following patients were excluded: six who underwent EVAS 
to reline previously inserted grafts; eleven chimney-EVAS patients; one patient who underwent EVAS 
for a ruptured AAA; six who had missing post-operative scans due to loss to follow-up (2), death 
after 30 days but before 1 year (3) and severe renal impairment contra-indicating contrast CT (1) and 
twelve who had not yet had their 1-year post-operative scan. The patient with renal impairment was 
followed up using X-Ray imaging and displayed no stent movement. Figure 5.1 is a visual 
representation of the patient selection.  
 
Figure 5. 1 Excluded patients with reasons  
 
Abbreviations: ChEVAS, Chimney Endovascular aneurysm sealing.  
68%
5%
10%
1%
5%
11%
Included Patients
Relining procedure
ChEVAS
Ruptured aneurysm
Missing scans
Less than 1 year follow-up
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5.1.2. Demographics and comorbidities  
76 patients (58 men) were included in this study with a mean (SD) age of 76 (7.4) years. The patient 
population is one with multiple comorbidities including cancer and encompasses a large proportion 
of smokers. Over 70% of patients had an American Society of Anaesthesiologists (ASA) grade of 3 or 
more.  Further details of demographics and comorbidities are displayed in Table 5.1.  
 
Table 5. 1 Demographics, comorbidities and ASA grade of the patient cohort 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Abbreviation ASA: American Society of Anaesthesiologists 
 
 
 
 
 
Characteristics Number (%) 
Gender Male 58 (76) 
Female 18 (24) 
Ischemic heart disease  35 (46) 
Respiratory disorders 26 (34) 
Diabetes 11 (14) 
Renal impairment 14 (18) 
Hypertension 60 (79) 
Cancer 8 (11) 
Number of 
Comorbidities 
  
 
 
0 6 (8) 
1 19 (25) 
2 26 (34) 
3 18 (24) 
4 6 (8) 
5 1 (1)  
Smoking  Ex-smoker 36 (47) 
Current 22 (29) 
ASA grade 2 22 (29)  
3 49 (64) 
4 5 (7) 
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5.1.3. Aorto-iliac anatomy  
The anatomical features of 20 patients (26%) were within both IFU-2013 and IFU-2016; 56 (74%) 
patients were within IFU-2013; of these, 35 were outside the new IFU-2016 (46% of the whole 
population; 63% of the outside IFU-2016 population); 21 patients were outside both IFU-2013 and 
IFU-2016 (28% of the whole population; 38% of the outside IFU-2016 population). Please see visual 
representation on Figure 5.2. The proportion of patients that were compliant with IFU-2013 but 
were classed outside the revised IFU-2016 (35 patients) had at least one of the following anatomic 
features: 23 (66%) had a ratio of maximum AAA diameter to maximum aortic blood lumen diameter 
>1.4, 14 (40 %) had an aortic neck diameter >28 mm but <32 mm and 1 (3%) had a distal seal zone 
length <10 mm (Table 5.2). Pre-operative anatomical data is displayed in Table 5.3. 
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Table 5. 2 Reasons for non-compliance with IFU-2013 and IFU 2016 
IFU-2013 n (%) IFU-2016 n (%) 
Iliac and femoral artery access that 
allows for atraumatic device 
introduction 
0  No Change - 
Aortic proximal neck diameter range of 
18 to 32mm 
13 (17) Aortic proximal neck diameter 
range of 18 to 28mm 
27 (36) 
Minimum aortic proximal neck length 
of ≥ 10mm 
3 (4) Criteria remains the same; 
however, the definition of aortic 
proximal neck length is updated to 
diameter change of 10% vs. 
previous 20% 
3 (4) 
Proximal aortic neck angulation of ≤60° 0 No Change - 
Aortic aneurysm with a blood lumen 
diameter of ≤60mm  
2 (3) Aortic aneurysm with a blood 
lumen diameter of ≤70mm 
2 (3) 
N/A - Ratio of maximum aortic aneurysm 
diameter to maximum aortic blood 
lumen diameter >1.4 
23 (30) 
Iliac arteries luminal diameter range of 
9 to 35mm 
5 (7) Iliac artery blood lumen diameter 
range of 9 to 35mm outside the 
distal seal zone  
Distal seal zone: length of ≥ 10mm 
and diameter range of 9 to 25mm 
6 (8) 
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Table 5. 3 AAA Characteristics according to instructions for use (IFU) 
Anatomical feature All patients Patients 
outside IFU-
2016 
Outside IFU-
2013 
Aortic neck length (mm) 27 (6-65) 29(6-65) 23 (10-54) 
Infra-renal neck angulation (degrees) 34 (0-78)  32 (0-77) 36 (0-70) 
Maximum neck diameter (mm) 27 (5) 28(5) 28 (7) 
Maximum aortic lumen diameter (mm) 44 (14) 41 (14) 42 (12) 
Maximum AAA diameter (mm) 60 (54-93) 63(54-93) 61 (55-91) 
Aortic bifurcation diameter (mm)  28 (14-54) 30(15-54) 29 (15-54) 
Maximum right common iliac artery 
diameter (mm) 
16 (4) 16(4) 16 (4)  
Maximum left common iliac artery diameter 
(mm) 
16 (4) 16(4) 16 (4) 
Abbreviations: IFU, instructions for use; AAA, Abdominal aortic aneurysm; 
Values are expressed as median (range) or mean (standard deviation). 
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5.1.4. Operative details 
EVAS was performed using paired stents in all but three patients, who received an aorto-uni-iliac 
(AUI) device. Five patients received additional planned interventions during the EVAS procedure; one 
patient received two additional procedures. These included an ilio-femoral bypass, two femoral 
endartectomies, an iliac extension and one patient underwent both an ilio-femorial bypass and a 
femoral endartectomy. All but five patients received general anaesthesia; the remaining five 
received regional anaesthesia (sub-arachnoid or epidural). The surgeons followed the EVAS 
technique as described in ‘Chapter 3: 3.6. EVAS in Liverpool’. To achieve proximal seal, surgeons 
routinely aimed to use the maximal length of neck available in each patient.  
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5.2. Procedural Outcomes 
5.2.1. Intra-Operative outcomes 
No deaths occurred intra-operatively. Five patients (7%) had intraoperative complications, two (3%) 
of which were due to device failure. The other complications were: one rupture of the distal external 
artery and two intraoperative AAA ruptures (asymptomatic, detected on the first follow-up CT). All 
non-device failure complications occurred in patients who were outside IFU-2016 but within IFU-
2013.  
The first device-failure was a rupture of the right stent balloon, which was successfully resolved by 
replacing the faulty catheter, as the stent had not been deployed and therefore could be taken out 
via the same deployment route with minimal femoral arterial damage. A new stent was then 
deployed into the AAA, with uneventful conclusion of the procedure. The anatomy of the AAA was 
outside IFU-2013 and IFU-2016. One year later, we found that this AAA had decreased in size (11% 
volume decrease; no significant diameter change) (Chapter 5.3) and the stents had not moved 
(Chapter 5.4).  
The second device failure was a ruptured endobag. This was as the result of a defect of the Nellix 
pressure transducer which displayed an incorrect pressure. The stent was already unsheathed and it 
was not possible to retract it without causing damage to the vessels in its exit route. The surgeons 
considered conversion to open repair, however the fitness of the patient was of concern. They 
decided to seal the AAA with the remaining endobag. A small type Ia endoleak was detected at final 
angiography in the operating room (Figure 5.3). This was not visible on CT 48 hours after the 
procedure. This patient was within both IFU-2013 and IFU-2016. One year later, the AAA had grown 
significantly (6mm diameter increase and 9% volume increase) (Chapter 5.3) with evidence of 
proximal displacement/migration in both stents (left 6mm and right 12mm) (Chapter 5.4) but still no 
visible endoleak. The team considered re-intervention, however the patient has severe COPD 
precluding even further endovascular treatment.  
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Figure 5. 2 Visible type 1A endoleak detected on final angiography in the operating room.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Final completion angiogram using contrast shows evidence of a very small type 1a endoleak. Arrows are 
pointing towards blood flow outside and around the endobag.  
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5.2.2. Thirty-day outcomes  
There were no post-operative deaths but 13 patients (17%) experienced a complication within 30-
days of EVAS. Six of the complications were found in patients who were within IFU-2016; seven were 
in patients outside IFU-2016, three of which were within the original IFU-2013. Seven patients (9% of 
whole population; 54% of complicated population) required a secondary intervention. Three of the 
patients requiring re-interventions were within IFU-2016; and four were outside IFU-2016, none of 
which were within the original IFU-2013. The patient with the identified type 1a endoleak, which 
was as result of the previously described intra-operative complication, was within IFU-2013. Table 
5.4 displays the 30-day morbidity and re-interventions.  
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Table 5. 4 Thirty-day outcomes 
Variable  n.(%) Details   
Outside IFU-2016 Within IFU-2016 
(n=20) Outside IFU-2013 and 
IFU-2016 (n=21) 
Outside IFU-2016; 
within IFU-2013 (n=35) 
Complications 13 
(17) 
1 Limb ischemia  
1 Access site 
haematoma 
1 AKI 
1 Paraparesis, acute 
coronary syndrome 
and neck of femur 
fracture 
1 Limb ischemia  
1 Left internal iliac 
coverage 
1 Hospital acquired 
pneumonia 
3 Limb ischemia 
1 contrast nephropathy 
and AKI 
1 Access site 
haematoma 
1 Hospital acquired 
pneumonia 
Re-
intervention 
7(9) 1 evacuation of 
haematoma 
1 Insertion of spinal 
drain and hip 
hemiarthroplasty 
1 Thrombectomy 
1 Angioplasty + 
stenting 
- 1 thrombectomy 
1 femorofemoral 
bypass + fasciotomies 
1 Embolectomy 
Endoleak 1(1) - - 1 Type Ia, resolved 
within 48h 
Death 0  - - - 
Abbreviations: AKI, Acute Kidney Injury  
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5.2.3 Follow-up outcomes  
Over a median follow-up of 24 months (range 12-48), a total of twelve patients underwent late re-
interventions of whom nine were outside IFU-2016. One patient was also outside IFU-2013 (Re-
interventions: 12% outside IFU-2016 vs 4% within IFU-2016). Three patients developed a type Ia 
endoleak: all were outside IFU-2016 with two also outside IFU-2013 (Endoleaks: 4% outside IFU-2016 
vs 0% within IFU-2016). All patients with an endoleak displayed a significant change in AAA volume; 
two of which were AAA growth (11%, 5.3%, -11%; the latter however also displayed diameter 
increase of 10mm) (Chapter 5.3).  All patients with an endoleak also had evidence of proximal 
displacement in at least one stent, with one patient also displaying migration (patient 1: right stent 
6.4 mm; patient 2: left stent 5.1 mm; patient 3: left 13.4 mm and right 13.8 mm) (Chapter 5.4). 
Outcomes beyond 30 days included 8 deaths, none AAA related (Late deaths: 9% outside IFU-2016 vs 
5% within IFU-2016). Re-interventions are summarised in Table 5.5.  
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Table 5. 5 Late Reinterventions 
Follow-up range 12-48 months, median: 24 months 
Variable  n.(%) Details   
Outside IFU-2016 Within IFU-2016 
(n=20) Outside IFU-2013 and 
IFU-2016 (n=21) 
Outside IFU-2016; 
within IFU-2013 (n=35) 
Re-
intervention 
12 
(16) 
1 External Iliac artery 
stent 
 
1 tibial bypass 
1 repeated EVAS 
1 superficial femoral 
artery angioplasty 
1 Limb extension 
1 Nellix-in Nellix ChEVAS 
1 Femoro-femoral 
bypass 
2 Conversion to open 
repair 
1 femoral thrombectomy 
and embolectomy  
1 thrombectomy and 
Tibial bypass  
1 Conversion to open 
repair 
Endoleak 3 (4) 2 Type Ia 1 Type Ia 0 
Death 8 (11) 3  
Not aneurysm related* 
4 
Not aneurysm related* 
4 
Not aneurysm related* 
ChEVAS: Chimney Endovascular aneurysm sealing: EVAS extending into the supra-renal segment using chimneys 
*General Practitioners (GPs) were contacted to confirm the cause of death.   
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5.3 Aneurysm growth  
5.3.1 Diameter Change  
All patients had a one-month post EVAS CT scan; 75 patients had a CT scan at one year; forty-six 
patients had a 2-year post-EVAS CT; seventeen had a CT scan at 3-years; and seven had a CT at 4 
years. Table 5.6 presents the extent and proportion of AAA growth, defined as an increase of ≥5mm 
in maximum AAA diameter over time. Just under a quarter of patients had AAA growth, detected at 
any time, by diameter change definition. The extent of significant diameter increase over time can 
be found on Figure 5.4. Figure 5.5 is of a survival plot of freedom from significant diameter increase 
over the 4 years. 
 
Table 5. 6 Proportion and extent of AAA growth (diameter change) over time. 
Time since 
procedure, years 
Number of 
patients 
AAA growth by diameter 
n.(%) 
Median diameter change 
(mm) (Range) 
1 year 75 5 (7) 6 (5-10)  
2 year 46 11 (24) 5 (5-12)  
3 year 17 4 (24) 8 (5-15)  
4 year 7 4 (57) 6.5 (5-10)  
At any time 76* 18 (24) 6 (5-15) 
*note that one patient had their second scan 2 years after EVAS. 
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Figure 5. 3 Maximum AAA diameter increase in patients with AAA growth by diameter and time of 
detection  
 
Bars represent patients with AAA diameter increase of 5mm or more. Each bar represents the patient’s latest 
maximum AAA diameter change. These are grouped into the different year groups according to when the latest 
diameter increase was noted. 
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Figure 5. 4 Freedom from AAA growth by diameter increase 
 
Event: diameter increase of ≥5mm. Survival table including standard errors over time can be found in appendix 
8.3; Table 8.7. Standard errors of more than 10% were excluded from the graph. 
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5.3.2. Absolute volume measurements  
We were able to obtain AAA volume measurements for all available scans. Table 5.7 shows the 
median AAA volume measurements at each time point. Figure 5.6 shows the absolute volume 
measurements over time. We found 2 patients with statistically extreme volume measurements, 
who had been followed up for one year. We re-measured volumes of their AAAs and obtained 
similar results (less than 5% difference).  
Table 5. 7 Absolute AAA volume over time 
Time since procedure Number of patients Median absolute volume (cm3) (Range) 
1 month 76 191 (88 - 965) 
1 year 75 192 (89 – 862) 
2 year 46 187 (92 – 394) 
3 year 17 196 (134 – 290) 
4 year 7 197 (149 – 310) 
One patient had their second scan at 2 years post-EVAS.  
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Figure 5. 5 Absolute volume measurements 
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5.3.3. Volume Change  
Table 5.8 presents the frequency of AAA growth of more than 5% at each post-operative time point. 
Just under one third of all AAAs demonstrated growth at one year; this proportion was more than 
double at 2 years and all but one AAA with a sufficiently long follow-up grew at years 3 and 4.  The 
extent of AAA growth also appeared to increase over time (Figure 5.7). Figure 5.8 is of a survival plot 
of freedom from AAA growth over the 4 years. There were 5 patients, of patients with AAA growth, 
in whom the volume decreased in a subsequent scan. This was more than 5 % in only one patient 
(5.7%).  
 
Table 5. 8 Proportion and extend of AAA growth (volume change) over time. 
Time since 
procedure, years 
Number of 
patients 
Frequency of 
volume increase 
n.(%) 
Median AAA 
growth (%) (Range) 
Median absolute 
volume change (mm3) 
(Range) 
1 year 75 24 (32) 11 (5.3-21)  22 (16-62) 
2 years 46 31 (67) 15 (6-50)  18 (9-29) 
3 years 17 16 (94) 26 (8-60)  31 (11-80) 
4 years 7 7 (100) 43 (18-65)  33 (24- 121) 
At any time 76 50 (66) 14 (5.3-65) 25 (9 -121) 
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Figure 5. 6 Most recent AAA volume change in patients with AAA growth and time of detection  
 
Bars represent patients with AAA volume increase of more than 5%. Each bar represents the patient’s latest 
AAA volume change. These are grouped into the different year groups according to when the latest volume 
increase was noted. 
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Figure 5. 7 Freedom from AAA volume increase 
 
Event: AAA volume increase of ≥5%. Survival table including standard errors over time can be found in appendix 
8.3; table 8.8. 
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5.3.4. Diameter measurements vs volume measurements  
We assessed the agreement of AAA volume and maximum dimeter and as expected all were 
significant at p< 0.01 (appendix 8.4; Table 8.17 and Figure 8.3).  The R values of the comparison of 
diameters and volume measurements at one month, one year, two years, three years and four years 
were 0.701, 0.859, 0.761, 0.721 and 0.772 respectively. For 25 patient (33%) there was no AAA 
growth detected by either method; 17 (22%) AAA growth cases were detected by both methods; 33 
(43%) were detected by volume measurements only and 1 (1%) was detected only by diameter 
measurements. For the rest of the thesis, we continue the analysis of AAA growth as detected by 
significant volume increase.  
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5.3.5. Aneurysm growth and IFU 
Table 5.9 displays the distribution of AAA growth within different IFU groups. Figure 5.9 displays the 
freedom from AAA growth over time of the different IFU groups. Log rank test revealed no statistical 
difference between different IFU groups Figure 11.  
Table 5. 9 AAA growth at any time in different IFU groups. 
 AAA growth n./N(%) 
IFU-2016 compliant 14/20 (70) 
IFU-2016 non-compliant 36/56 (64) 
IFU-2013 compliant 
(Non-compliant with IFU-
2016) 
24/35 (69) 
Non-compliant with IFU-
2013 and IFU-2016 
12/21 (57) 
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Figure 5. 8 Freedom from AAA growth in different IFU groups. 
 
Event: AAA volume increase of ≥5%. IFU-2016 compliant: dotted line; IFU-2013 compliant (Non-compliant with 
IFU-2016): line and dot line; Non-compliant with IFU-2013 and IFU-2016: continuous line. Standard errors for 
each group at specified points can be found in appendix 8.3; Table 8.9. The reference lines specify the point at 
which the standard error exceeded 10% for a specific group; the pattern of the reference line corresponds to 
the group with the same pattern of the survival curve. The dotted reference line at 400 days: IFU-2016 
compliant group. The continuous reference line at 419 days: Non-compliant with IFU-2013 and IFU-2016. Log 
Rank test results displayed no significant p values (appendix 8.3; Table 8.10). 
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5.3.6. Patterns and causes of changes in volume 
Extensive numerical data of the linear mixed model (LMM) results can be found in Appendix 8.5. 
Approximately 95% of the total variation in volume was due to inter-individual differences (appendix 
8.5; step 1).  
When assessing individual variation in AAA volume over time (appendix 8.5; step 2), time was 
statistically significant (p=0.000). This confirms that AAA volume changed over time. AAA mean 
estimated initial volume (at one month) was 196 cm3 and this increased by 9.4 cm3 per annum (p= 
0.000). The correlation between the initial volume and the trajectories of growth were found to be 
significant with an overall negative estimate (β= -921.4; p=0.011). This suggests that smaller AAAs 
grew faster than larger ones.  
We assessed whether the rate of AAA growth accelerated or decelerated over time (appendix 8.5; 
Step 3 and 4). Our results suggested that the initial increase was slow however it accelerated before 
slowing down again. (All relevant factors: p<0.05) (Figure 5.10).  
Finally we applied potential predictors to the model to elicit any relevant associations (appendix 8.5; 
step 5). These included: age, neck angulation, neck length, neck diameter, ratio of maximum AAA 
diameter to maximum AAA lumen diameter, proximal displacement, migration. Neck diameter and 
migration were significantly associated with AAA volume growth (p=0.007 and p=0.036, 
respectively). 
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Figure 5. 9 Mean Predicted Values of all AAAs over time.  
 
Results from the model with the best fit was applied: cubic growth curve model. 
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5.4. Stent movement  
5.4.1. Absolute stent movement values  
Over the 4-year period, forty-two patients had proximal displacement of ≥4mm in one or more 
stents. 25 were first detected within one year (33% of the point population of 75), 12 were detected 
at two-year follow-up (26% of the point population of 46) and a further six at 3-year follow-up (35% 
of the point population of 17).  
Sixteen patients had migration of >10mm: five were first detected at one year (7% of point 
population of 75); seven at two years (15% of point population of 46); three at three years (18% of 
point population of 17) and one at 4 years (14% of point population of 7).  
There were no differences in the incidence of proximal displacement/migration between the left and 
right stents (Table 5.10). Figure 5.11 shows the evolution of proximal displacement and migration 
over time. Figure 5.12 shows freedom from proximal displacement and migration. 
 
Table 5. 10 Incidence and extent of proximal displacement and migration at any time. 
 Total patient 
number 
Proximal 
displacement  
n(%) 
Migration  
n(%) 
Median 
proximal 
displacement 
(range)a (mm) 
Median 
migration 
(range)b (mm) 
≥4mm >10mm ≥4mm >10mm 
Left stent 74 32(43) 10(14) 7.4(4-35) 16(12-35) 
Right stent 75 35(47) 14(19) 8.2(4-28) 15(10.3-28) 
Per patient 76 42(55) 16(21) 7.6(4-35) 15(10.3-35) 
aamong patients with proximal displacement, stent movement on most recent scan 
bamong patients with migration, stent movement on most recent scan 
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Figure 5. 10 Distance between stent and superior mesenteric artery in patients with migration (11a and 11b) and proximal displacement (11c and 11d) over 
time. 
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Figure 5. 11 Freedom from proximal displacement (11a) and migration (11b, 11c) 
 
Figure 11a is of freedom from proximal displacement. Figure 11b is of the survival curve for migration including all data, the reference line set at 1334 days is the point at 
which the standard error has exceeded the 10% mark in one of the groups. 11c cuts off the data beyond 1334 days. Standard errors at specified points can be found in 
appendix 8.3; Table 8.11.
a b
 
c 
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5.4.2. Stent movement and IFU  
Proximal displacement/migration was affected by compliance with IFU-2013 and IFU-2016, as 
summarized in Table 5.11. The highest incidence of proximal displacement (66%) was observed 
when the device was outside both IFUs; this reduced to (30%) when the procedure was within the 
new IFU (IFU-2016). Figure 5.13 and 5.14 show freedom from proximal displacement and migration 
of each of the IFU groups. Proximal displacement was significantly more frequent among patients 
whose anatomy did not conform to any IFU (p=0.025). 
 
Table 5. 11 Stent movement at any time in different IFU groups. 
 Proximal displacement n./N 
(%) 
Migration n./N (%) 
IFU-2016 compliant 6/20 (30) 2/20 (10) 
IFU-2016 non-compliant 36/56 (64) 14/56 (25) 
IFU-2013 compliant 
(Non-compliant with IFU-
2016) 
22/35 (63) 9/35 (26) 
Non-compliant with IFU-
2013 and IFU-2016 
14/21 (66) 5/21(24) 
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Figure 5. 12 Freedom from proximal displacement in IFU groups 
 
Event: proximal displacement. IFU-2016 compliant: dotted line; IFU-2013 compliant (Non-compliant with IFU-
2016): line and dot line; Non-compliant with IFU-2013 and IFU-2016: continuous line. Standard errors for each 
group at specified points can be found in appendix 8.3; Table 8.12. The reference lines specify the point at 
which the standard error exceeded 10% for a specific group; the pattern of the reference line corresponds to 
the group with the same pattern of the survival curve. The dotted reference line at 487 days: IFU-2016 
compliant. The continuous reference line at 390 days: Non-compliant with IFU-2013 and IFU-2016. There was 
no statistically significant difference between curves (appendix 8.3; Table 8.13). 
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Figure 5. 13 Freedom from migration in IFU groups 
 
Event: Migration. IFU-2016 compliant: dotted line; IFU-2013 compliant (Non-compliant with IFU-2016): line and 
dot line; Non-compliant with IFU-2013 and IFU-2016: continuous line. Standard errors for each group at 
specified points can be found in appendix 8.3; Table 8.14. The reference lines specify the point at which the 
standard error exceeded 10% for a specific group; the pattern of the reference line corresponds to the group 
with the same pattern of the survival curve. The line and dot reference line at 783 days: IFU-2013 compliant 
(Non-compliant with IFU-2016). The continuous reference line at 751 days: Non-compliant with IFU-2013 and 
IFU-2016. There was no statistically significant difference between curves (appendix 8.3; Table 8.15). 
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5.5. Aneurysm growth and Stent movement  
Diameter increase was significantly associated with both migration and proximal displacement 
(p=0.000 and p=0.007, respectively). Significant volume increase was not associated with any stent 
movement (migration: p=0.236 and proximal displacement: 0.332).   
In eight patients volume increase preceded proximal displacement; in five patients proximal 
displacement proceeded volume increase; in eighteen patients proximal displacement and volume 
increase were detected at the same time. Twenty patients only had volume increase and eleven only 
had proximal displacement. Fourteen patients displayed neither proximal displacement nor volume 
increase.   
In four patients volume increase preceded migration; no patients displayed migration before volume 
increase; in nine patients migration and volume increase were detected at the same time. Thirty-
eight patients only had volume increase and three only had migration. Twenty-two patients 
displayed neither migration nor volume increase.   
In three patients diameter increase preceded proximal displacement; in seven patients proximal 
displacement preceded diameter increase; in five patients proximal displacement and diameter 
increase were detected at the same time. Three patients only had diameter increase and twenty-
seven only had proximal displacement. Thirty-one patients displayed neither proximal displacement 
nor diameter increase.   
In two patients diameter increase preceded migration; in one patients migration preceded diameter 
increase; in seven patients migration and diameter increase were detected at the same time. Eight 
patients only had diameter increase and six only had migration. Fifty-two patients displayed neither 
migration nor diameter increase.  
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Table 5. 12 Summary of the timing of AAA growth in relation to stent movement. 
 Proximal 
displacement and 
Volume increase 
Migration and 
Volume increase  
Proximal 
displacement 
and diameter 
increase  
Migration and 
diameter 
increase  
AAA growth 
only 
20 38 3 8 
Stent 
movement only 
11 3 27 6 
AAA growth 
occurring first 
8 4 3 2 
Stent 
movement 
occurring first  
5 0 7 1 
AAA growth 
and stent 
movement 
occurring at the 
same time  
18 9 5 7 
Neither 
occurring  
14 22 31 52 
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Chapter 6: Discussion  
Summary of findings  
Our primary hypothesis was that AAA growth continues after EVAS. This study confirms that AAA 
growth post-EVAS occurs in a significant proportion of patients. AAA growth is progressive, with 
smaller AAAs growing faster than larger ones. Our secondary hypothesis was that AAA growth is 
associated with stent movement and non-compliance with anatomical criteria of the Nellix IFU. We 
demonstrated that stent graft movement is frequent and is associated with anatomy outside the 
current IFU.  Stent graft displacement can be progressive, can affect one or both stents and is 
associated with AAA growth, a finding that had not been previously described. We did not find an 
association between AAA growth and compliance with IFU.  
 
Comparison with relevant literature  
There is little data, in the literature, on AAA growth post-EVAS, which has not been widely reported 
using volume measurements. Zoethout et al reported the two-year outcomes of a multi-centre study 
based in the Netherlands.249 They compared results of 168 patients who were within IFU-2013 to a 
subgroup of 48 patients who were also within IFU-2016 (22%); patients outside of IFU-2013 were not 
included in this study (96 patients). They reported AAA growth by diameter (SVS definition) in ten 
patients (6 %), two of which were within IFU-2016 (6 % vs 4.2 %).249 Migration, which was defined as 
movement of 10 mm or more, occurred in 12 patients (7.1 %), none within IFU-2016 (7.1 % vs 0 %). 
They defined caudal movement as movement between 5 and 10 mm and this was observed in 25 
patients (14.9 %), with four in the IFU-2016 group (14.9 % vs 8.3 %). This patient cohort was 
complicated by 9 late type I endoleaks (5.4 %) (one type Ib), of which 3 were in patients whose 
anatomy was IFU-2016 (5.4 % vs 6.3 %). Notwithstanding, the shorter length of follow-up, the 
incidence of endoleaks is similar to that in our study (5.4% vs 3.9%). However, AAA growth and stent 
movement were lower within this cohort. There are several factors that may have warranted this 
difference. First, the above study excluded the analysis of patients outside IFU-2013, whilst our 
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cohort included these. A further possible contributor to this differences may be discrepancies in 
measurement technique, as the above study did not describe this within their study. Additionally, 
only 26 patients within IFU-2016 had a follow-up of more than one year. The baseline CT scans were 
not performed at the same time in all patients, with 12% taking place after 6 months post-EVAS; 
further, only approximately 50% of patients underwent a CT scan at 2 years. Our study demonstrates 
that, when using the SVS definition for stent movement, detection is increasingly more frequent 
during follow-up (7% detection rate at one year, 15% at two years, 18% at three years and 14% at 4 
years).  Whilst AAA growth, by diameter definition, was detected in 7% of patients at one year but 
reached 24% at years two and three.  
Migration and other types of stent displacement have also been described by other authors, 
although definition and measurement techniques have not been consistent in the literature. England 
et al previously reported, in a small cohort of our patients with shorter follow-up, the occurrence of 
post-EVAS stent migration, defined as and measured with the same criteria used in the present 
study as proximal displacement.237 This study included 18 patients of which five displayed proximal 
displacement at one year follow-up in one or both stents (28%). Our study, which included the 
patient studied by England et al, detected proximal displacement in 33% of patients at one year (25 
of 75 patients). Dorweiler et al described stent movement of ≥5mm occurring in 6 out of 24 patients 
at one year (25%).250 However, Gossetti et al, in a multi-centre national registry, reported that only 
two out of 267 patients displayed stent movement of >4mm at one year (0.7%).251 This study did not 
describe the method used to detect or measure movement. Only 67% of patients had a baseline 
CT/MRI scan, and it appears that other modalities, such as ultrasound scan, were used to obtain 
measurements. Van Veen et al reported stent movement of >5 mm in 6 out of 54 patients (11%) at 
one year post-EVAS in a study describing a new technique of capturing stent movement using 3-
dimensional modalities on CT scans.252 This study included a ‘majority’ of patients within IFU-2013, 
whilst in our study more than one-quarter were outside IFU-2013. It did not describe the number of 
patients in each of the IFU groups. Carpenter et al also reported migration (by SVS defintion) at one 
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year in three of 129 patients (2.3%) within IFU-2013. This migration was not associated with AAA 
growth (by SVS definition), endoleak or reintervention.253 Description of measurement technique 
was also missing from this study.  
In contrast, Van den Ham et al. did not observe stent movement at one year in 50 patients.254 
Although the authors stated that 38 patients were within IFU (76 %), it is unclear which IFU they 
were referring to. This study did not define the threshold of stent movement used. CT scans were 
assessed for anatomical changes and device stability. AAA volume was also measured and no 
difference was detected between overall post-EVAS scans.  In our study we assessed AAA growth by 
volume using a different criteria with a set definition, it is, therefore difficult to compare the two 
studies.  
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Table 6. 1 AAA growth and stent movement within the current literature 
Relevant 
study 
Number of 
patients 
AAA 
growth 
definition  
AAA 
growth n. 
(%) 
Stent 
movement 
definition  
Stent 
movement 
n. (%)  
Median 
Imaging 
Follow-up  
Zoethout et 
al255 
168 >5mm 
diameter 
change  
10 (6) ≥10 mm 
Or  
≥5 mm and 
requiring 
intervention 
12 (7.1) 23 months 
5-10 mm  
 
25 (15) 
England et 
al237 
18 N/A N/A >4mm  5 (28) 12 months 
Dorweiler 
et al250 
24 Diameter 
change; 
Threshold 
unclear 
1 (4.2) 
7mm 
increase 
 
≥5mm 6 (25) 12 months  
Gossetti et 
al256 
267 >5mm 
diameter 
change 
2 (0.7)* >4mm 2 (0.7) 12 months 
Van Veen 
et al257 
54 N/A N/A >5mm 6 (11) 12 months 
Carpenter 
et al253 
129 >5mm 
diameter 
change 
2(1.6) >10mm 3(2.3) 12 months 
Van den 
Ham et al254 
50 Volume; no 
set 
threshold  
No overall 
growth 
Threshold 
unclear 
0 (0) 12 months 
*It is unclear if the whole cohort was assessed, as the two patients with AAA enlargement were reported as an 
added point in endoleak results.  
 
 
 
P a g e  | 79 
 
 
We used two methods to report AAA growth. Volume measurements capture AAA growth over the 
whole AAA; this is important as the shape of the AAA may change and thrombus may grow away 
from the maximal cross-sectional area. In other words, a change of shape and volume may occur 
without significant changes in maximum diameter. This may be more likely post EVAS than post 
EVAR, as transmission of pressure from the landing zones may not occur uniformly in a sealed AAA. 
Volume measurements have been used to report changes in AAA post-EVAR using the same 
definition for change.258 As EVAS is a relatively new technique, it may be appropriate to use the most 
sensitive method available to detect AAA growth. However, volume measurements, as described in 
this thesis, are cumbersome and time consuming, whereas automated methods are imprecise. 
Improvement in software would be necessary for volume measurement to be adopted more widely. 
The incidence of migration and proximal displacement in our study should be interpreted in context, 
by comparing it to that observed post standard EVAR, when measured with similar criteria. A recent 
systematic review demonstrated a 6.3 % incidence of post-EVAR migration (≥5 mm) at 1-3 years; this 
was associated with poor anatomy and, unlike in our study, with type Ia endoleaks.259 
Despite the occurrence of migration, proximal displacement and AAA growth in a substantial 
proportion of patients, we only observed three late endoleaks. It is generally thought that AAA 
growth rarely occurs in absence of AAA perfusion and pressurisation. It is also accepted that AAA 
pressurisation post-EVAS can occur in absence of a visible endoleak.233 Considering the incidence of 
AAA growth observed in our study, we are concerned that this may be occurring in our patients. Our 
findings thus suggest that even small degrees of proximal displacement (≥4 mm) may be clinically 
significant. It is possible that small movements may allow blood to seep between the endobags and 
the aorta, or between the two endobags, effectively creating a wedge-like communication between 
the proximal circulation and the AAA.  Even after thrombosis of such communication, AAA growth 
may occur, as thrombus is capable of transmitting pressure.260 AAAs treated with EVAS may thus 
behave differently from those treated with EVAR during follow up.  
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In support of this thesis, our group recently highlighted the potential effect of certain forces (such as 
gravity and vibration) on implanted Nellix prostheses;261 these forces would not be expected to have 
the same effect post-EVAR, due to the difference in mass between traditional endografts and the 
Nellix prosthesis. Whilst it is still unclear whether such effects have significant clinical consequences, 
their observation underlines that post-treatment evolution of AAAs treated by EVAS may be 
different from that of AAAs treated by EVAR. 
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Strengths and Limitations 
This study has obvious limitations, as it was retrospective, limited to a single centre and to a 
relatively small population. Its strengths, however, include the prospective nature of clinical data 
collection, ensuring comprehensive capture of clinical adverse events, the low rate of loss to follow-
up and the previously validated CT measurement techniques.  
Whilst proximal stent displacement may be of particular relevance in short aortic necks, its clinical 
impact would also depend on the length of endobag/aorta apposition at the landing zones (the 
“seal”). In our experience, however, on CT scans, it is not always possible to measure length of seal, 
particularly in narrow necks, where the contour of endobags is difficult to define. We thus decided 
not to include this variable in this study, as we were not confident on our ability to measure it 
reliably. This is a potential weakness of this research, as we were not able to demonstrate adequate 
proximal seal in all patients post EVAS. It is now clear that it is difficult to utilise the proximal landing 
zone in full, when performing EVAS.231 It is notable, however, that the surgeons performing EVAS in 
Liverpool always aimed to utilise all the available neck, when deploying the stents, thus any shortfall 
may be inherent to the very nature of the Nellix endoprosthesis, which is difficult to deploy 
precisely.  
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Further Considerations 
We chose to use two definitions for stent movement, one being the SVS EVAR standard (>10 mm), 
which is more than 15 years old.242 We believe that this definition, whilst established in the 
literature, may be outdated and inappropriate, partly because modern cross-sectional imaging 
allows the detection of much smaller stent movements, but also because of the inherent differences 
between EVAR and EVAS, which seals the AAA without active fixation at the landing zones (i.e. 
without radial force and/or hooks and barbs). As aortic necks are rarely perfectly cylindrical, even 
small post-EVAS stent movements may result in loss of contact between the endobags and the aorta 
(or between the two endobags), with consequent loss of seal and re-pressurization of the AAA.  For 
these reasons, we also reported stent movement according to a less conservative (≥4 mm) definition 
previously used for fenestrated EVAR and EVAS.237, 262 Interestingly, IFU 2016 compliant patients 
displayed approximately half the incidence of stent movement of the rest of the patients, regardless 
of definition (≥4 mm or >10 mm). As previously noted, there are many different measurement 
techniques and definition thresholds within the current literature, hence we believe that a new 
consensus is required on definitions in order to make meaningful comparisons between studies.  
Whilst it is logical to assume that AAA growth follows stent movement, it is also theoretically 
possible that stent movement could be secondary to AAA growth, as such growth would create 
additional space for the stent/endobag complex to move into.  In support of this theory, we 
observed AAA growth before stent movement in some cases. Unfortunately, our study cannot 
establish whether AAA growth was the cause or the consequence of stent movement. Further 
research is necessary to clarify this relationship.  
Our findings confirm that there is a reduction in the incidence of stent movement when complying 
with IFU-2016, which was introduced after a higher than expected incidence of migration observed 
in American pre-marketing studies.263 However, proximal displacement still occurred in almost one 
third of patients whose anatomy complied with IFU-2016. Our results should thus encourage 
clinicians to pursue close surveillance even in patients treated within IFU for early detection of stent 
P a g e  | 83 
 
 
movement and AAA growth. They also support the notion that CT remains the cornerstone of post-
EVAS follow-up imaging, despite the relatively high radiation exposure it entails. Other modalities, 
such as ultrasound scan (US), cannot produce reliable measurements of AAA volume or quantify 
stent graft displacement. 
EVAS was readily embraced by the vascular community in 2013 with great optimism. The unfounded 
early belief that the sac-anchoring nature of the Nellix device would make stent movement 
impossible led clinicians to use EVAS on patients with poor anatomy and, in particular, very short 
necks.226 Our results demonstrate that the device was indeed embraced too quickly and that the 
assumptions EVAS relies on are flawed. Our data also suggests that strict IFU compliance may only 
mask these flaws, rather than address them substantially. It is our opinion that active fixation at the 
landing zones may prevent some of the migration/displacement observed after EVAS and, possibly, 
reduce the incidence of AAA growth.  
Our experience confirms that type II endoleaks post-EVAS are exceptionally rare. It is thus possible 
that changes in stent design that reduce or eliminate migration and proximal displacement may re-
invigorate the enthusiasm for AAA sealing. 
It is notable that, despite our findings on surveillance imaging, our clinical results are still acceptable, 
considering the treated population.  Nevertheless, we do not think that clinicians should offer EVAS 
as a routine AAA treatment as long-term clinical data is still unavailable, and because our imaging 
findings appear progressive in nature. Further, our research was not designed to evaluate clinical 
outcome: larger comparative studies (with EVAR, open surgery or conservative management as 
comparators) would be required for this purpose.  
It is debatable whether all patients treated by EVAS should be systematically recalled and informed 
of potential late post-EVAS complications. In view of our reassuring clinical results, and the fact that 
many of our patients are elderly and often unfit for further intervention, we have, so far, taken 
further action on a case-by-case basis. 
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Recommendations for Future Research 
The present study was performed on a small sample size; this study on a larger multi-centre study 
sample with longer follow-up would provide the means of validating our finding and making robust 
associations. This would especially be useful when assessing the direction of the association 
between stent movement and aneurysm growth.  
Assessment of endobag volume could facilitate the calculation of thrombus volume change over 
time and possibly explain the source of AAA growth (endobag volume subtracted from total AAA 
volume). Separation of the two endobags, which may be secondary to pressure within the AAA sac 
was not evaluated in our study, but has been described in the literature as an ominous sign.264 
EVAS possess a unique appearance on CT imaging. Long term clinical studies matched to imaging 
findings are important to broaden the knowledge base and optimise complication predictions.  
Our study suggests that diameter measurements are less sensitive than volume measurements, 
however, the method used in this study is time consuming and requires precise manual 
readjustments. Software developments to produce reliable automated volume measurements 
would be beneficial in assessing AAA growth post-EVAS in clinical practice.  
Research and development of the present Nellix endoprosthesis with active fixation at landing zones 
may resolve the stent movement incidence. For this, mathematical modelling of a new adapted 
EVAS device would be needed, along with testing in engineering laboratory.  
Large, multicentre comparative studies with EVAR would be useful to explore post-EVAS outcomes in 
context, and may provide a better understanding of the efficacy and cost effectiveness of EVAS.  
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Conclusion 
Patients treated with EVAS are prone to AAA growth, irrespective of whether their aortic anatomy 
was IFU-compliant. Although post-EVAS endoleaks (as defined for EVAR) are rare, re-pressurisation 
of a sealed AAA may thus occur even when flow is not demonstrated within it. EVAS can also be 
complicated by stent movement, particularly when performed outside IFU. AAA growth is associated 
with stent movement, however it is unclear which is the cause and which is the effect. Clinicians 
should continue close surveillance post EVAS, particularly in patients treated outside IFU. 
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Appendix  
8.1. STROBE Statement 
Table 8. 1 Checklist of items that should be included in reports of cohort studies 
 
Item 
No Recommendation 
 Title and abstract 1 (a) Indicate the study’s design with a commonly used term in the title or 
the abstract 
(b) Provide in the abstract an informative and balanced summary of what 
was done and what was found 
Introduction 
Background/rationale 2 Explain the scientific background and rationale for the investigation 
being reported 
Objectives 3 State specific objectives, including any prespecified hypotheses 
Methods 
Study design 4 Present key elements of study design early in the paper 
Setting 5 Describe the setting, locations, and relevant dates, including periods of 
recruitment, exposure, follow-up, and data collection 
Participants 6 (a) Give the eligibility criteria, and the sources and methods of selection 
of participants. Describe methods of follow-up 
(b) For matched studies, give matching criteria and number of exposed 
and unexposed 
Variables 7 Clearly define all outcomes, exposures, predictors, potential 
confounders, and effect modifiers. Give diagnostic criteria, if applicable 
Data sources/ 
measurement 
8*  For each variable of interest, give sources of data and details of methods 
of assessment (measurement). Describe comparability of assessment 
methods if there is more than one group 
Bias 9 Describe any efforts to address potential sources of bias 
Study size 10 Explain how the study size was arrived at 
Quantitative variables 11 Explain how quantitative variables were handled in the analyses. If 
applicable, describe which groupings were chosen and why 
Statistical methods 12 (a) Describe all statistical methods, including those used to control for 
confounding 
(b) Describe any methods used to examine subgroups and interactions 
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(c) Explain how missing data were addressed 
(d) If applicable, explain how loss to follow-up was addressed 
(e) Describe any sensitivity analyses 
Results 
Participants 13* (a) Report numbers of individuals at each stage of study—eg numbers 
potentially eligible, examined for eligibility, confirmed eligible, included 
in the study, completing follow-up, and analysed 
(b) Give reasons for non-participation at each stage 
(c) Consider use of a flow diagram 
Descriptive data 14* (a) Give characteristics of study participants (eg demographic, clinical, 
social) and information on exposures and potential confounders 
(b) Indicate number of participants with missing data for each variable of 
interest 
(c) Summarise follow-up time (eg, average and total amount) 
Outcome data 15* Report numbers of outcome events or summary measures over time 
Main results 16 (a) Give unadjusted estimates and, if applicable, confounder-adjusted 
estimates and their precision (eg, 95% confidence interval). Make clear 
which confounders were adjusted for and why they were included 
(b) Report category boundaries when continuous variables were 
categorized 
(c) If relevant, consider translating estimates of relative risk into absolute 
risk for a meaningful time period 
Other analyses 17 Report other analyses done—eg analyses of subgroups and interactions, 
and sensitivity analyses 
Discussion 
Key results 18 Summarise key results with reference to study objectives 
Limitations 19 Discuss limitations of the study, taking into account sources of potential 
bias or imprecision. Discuss both direction and magnitude of any 
potential bias 
Interpretation 20 Give a cautious overall interpretation of results considering objectives, 
limitations, multiplicity of analyses, results from similar studies, and 
other relevant evidence 
Generalisability 21 Discuss the generalisability (external validity) of the study results 
Other information 
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Funding 22 Give the source of funding and the role of the funders for the present 
study and, if applicable, for the original study on which the present 
article is based 
*Give information separately for exposed and unexposed groups. 
 
Note: An Explanation and Elaboration article discusses each checklist item and gives methodological 
background and published examples of transparent reporting. The STROBE checklist is best used in 
conjunction with this article (freely available on the Web sites of PLoS Medicine at 
http://www.plosmedicine.org/, Annals of Internal Medicine at http://www.annals.org/, and Epidemiology at 
http://www.epidem.com/). Information on the STROBE Initiative is available at http://www.strobe-
statement.org. 
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8.2. Data collection  
Table 8. 2 Variables Considered for Data Collection and Data Input 
Category Independent variable Data Input 
Demographic Age Years 
Sex Male or Female 
Comorbidities Ischemic heart disease Yes or No 
Reparatory chronic disorders  Yes or No 
Diabetes Yes or No 
Renal Impairment Yes or No 
Hypertension  Yes or No 
Cancer Yes or No 
Smoking Yes or No 
 ASA Grade Grade 1 to 5 
Medications Antiplatelet  Yes or No 
Statin Yes or No 
Anticoagulants  Yes or No 
 
Table 8. 3 Aortic anatomical variables considered for Data Collection and Data Input 
Category Independent variable Data Input 
Aortic Anatomical data  Neck length   Number 
Neck angulation  Number 
Neck diameter  Number 
Neck calcification/thrombus Number 
Shape of neck   Number 
Maximum aortic lumen diameter Number 
Diameter at aortic bifurcation Number 
Maximum R CIA diameter Number 
Maximum L CIA diameter Number 
Diameter at R iliac bifurcation Number 
Iliac tortuosity Number 
Maximum access diameter Number 
Maximum AAA diameter Number 
Instructions for use (IFU) Within IFU-2013 Yes or No 
Within IFU-2016 Yes or No 
Reason outside IFU Free-Text 
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Table 8. 4 Operative variables considered for Data Collection and Data Input 
Category  Independent variable  Data input 
Operative factors  Procedure  Free-Text  
Anaesthesia  General or local 
Intra-operative 
complication/events  
Free-Text 
 
Table 8. 5 Outcome variables considered for Data Collection and Data Input 
Category Independent variable Data Input 
30-day outcomes Inpatient Days 
ICU Days 
Complication Yes or No 
Complication type Free-Text 
Re-Intervention  Yes or No 
Re-Intervention Type Free-Text 
Endoleak Yes or No 
Endoleak type Free-Text 
Death Yes or No 
Cause of Death Free-Text 
Follow-up Outcomes Maximum Follow-up Months 
Re-Intervention Yes or No 
Re-intervention Type Free-Text 
Endoleak  Yes or No 
Endoleak Type Free-Text 
Death  Yes or No 
Cause of Death Free-Text 
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Table 8. 6 Measurement variables considered for Data Collection and Data Input 
Category Independent variable Data Input 
Time of CT scan  One month Days  
One year Days  
Two years Days 
Three years Days 
Four years Days 
Volume measurements One month AAA volume  Number 
One year AAA volume Number 
Two years AAA volume Number 
Three years AAA Volume  Number 
Max diameter measurements  One month AP  Number 
One month Reconstructed   Number 
One Year AP Number 
One year Reconstructed  Number 
Two years AP Number 
Two years Reconstructed  Number 
Three years AP Number 
Three years Reconstructed  Number 
Four years AP Number 
Four years Reconstructed  Number 
Stent movement data Left: Distance at one month Number 
Right: Distance at one month Number 
Left: Distance at one year* Number 
Right: Distance at one year* Number 
Left: Distance change one 
month to one year* 
Number 
Right: Distance change one 
month to one year* 
Number 
Left: stent movement at one 
year* 
Yes or No 
Right: stent movement at one 
year* 
Yes or No 
*same independent variables for two year CT scan, three year CT scan and four year CT scan 
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8.3. Kaplan-Meier curves survival tables  
Table 8. 7 Survival Table of freedom from AAA maximum diameter increase 
Survival Table 
 Time Status 
Cumulative Proportion Surviving at 
the Time N of Cumulative 
Events 
N of Remaining 
Cases Estimate Std. Error 
1 304.000 .00 . . 0 75 
2 325.000 1.00 .987 .013 1 74 
3 344.000 1.00 .973 .019 2 73 
4 350.000 .00 . . 2 72 
5 351.000 .00 . . 2 71 
6 351.000 .00 . . 2 70 
7 352.000 .00 . . 2 69 
8 360.000 .00 . . 2 68 
9 363.000 .00 . . 2 67 
10 364.000 .00 . . 2 66 
11 365.000 .00 . . 2 65 
12 366.000 .00 . . 2 64 
13 370.000 .00 . . 2 63 
14 371.000 .00 . . 2 62 
15 374.000 .00 . . 2 61 
16 379.000 .00 . . 2 60 
17 381.000 1.00 . . 3 59 
18 381.000 1.00 .941 .029 4 58 
19 381.000 .00 . . 4 57 
20 383.000 .00 . . 4 56 
21 387.000 .00 . . 4 55 
22 390.000 .00 . . 4 54 
23 394.000 .00 . . 4 53 
24 403.000 .00 . . 4 52 
25 408.000 .00 . . 4 51 
26 408.000 .00 . . 4 50 
27 410.000 .00 . . 4 49 
28 421.000 .00 . . 4 48 
29 441.000 .00 . . 4 47 
30 447.000 .00 . . 4 46 
31 487.000 1.00 .920 .035 5 45 
32 577.000 1.00 .900 .040 6 44 
33 680.000 1.00 .880 .044 7 43 
34 688.000 1.00 .859 .047 8 42 
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35 700.000 .00 . . 8 41 
36 707.000 .00 . . 8 40 
37 710.000 .00 . . 8 39 
38 713.000 1.00 .837 .051 9 38 
39 714.000 1.00 .815 .054 10 37 
40 714.000 .00 . . 10 36 
41 715.000 .00 . . 10 35 
42 718.000 .00 . . 10 34 
43 728.000 .00 . . 10 33 
44 731.000 .00 . . 10 32 
45 732.000 .00 . . 10 31 
46 734.000 1.00 .789 .058 11 30 
47 735.000 .00 . . 11 29 
48 737.000 .00 . . 11 28 
49 740.000 1.00 .761 .063 12 27 
50 751.000 .00 . . 12 26 
51 754.000 .00 . . 12 25 
52 760.000 .00 . . 12 24 
53 767.000 .00 . . 12 23 
54 773.000 .00 . . 12 22 
55 780.000 .00 . . 12 21 
56 783.000 1.00 .724 .069 13 20 
57 784.000 .00 . . 13 19 
58 784.000 .00 . . 13 18 
59 803.000 .00 . . 13 17 
60 805.000 .00 . . 13 16 
61 970.000 .00 . . 13 15 
62 1078.000 .00 . . 13 14 
63 1087.000 .00 . . 13 13 
64 1091.000 1.00 .669 .083 14 12 
65 1092.000 .00 . . 14 11 
66 1098.000 .00 . . 14 10 
67 1106.000 .00 . . 14 9 
68 1115.000 .00 . . 14 8 
69 1147.000 1.00 .585 .107 15 7 
70 1176.000 .00 . . 15 6 
71 1334.000 1.00 .488 .126 16 5 
72 1443.000 .00 . . 16 4 
73 1456.000 1.00 .366 .142 17 3 
74 1457.000 .00 . . 17 2 
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75 1465.000 1.00 .183 .147 18 1 
76 1490.000 .00 . . 18 0 
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Table 8. 8 Survival Table of freedom from AAA volume increase 
Survival Table 
 Time Status 
Cumulative Proportion Surviving at 
the Time N of Cumulative 
Events 
N of Remaining 
Cases Estimate Std. Error 
1 30.000 1.00 .987 .013 1 75 
2 304.000 .00 . . 1 74 
3 325.000 .00 . . 1 73 
4 343.000 1.00 .973 .019 2 72 
5 350.000 .00 . . 2 71 
6 351.000 1.00 .960 .023 3 70 
7 351.000 .00 . . 3 69 
8 352.000 .00 . . 3 68 
9 353.000 1.00 .946 .027 4 67 
10 357.000 1.00 .931 .030 5 66 
11 360.000 1.00 .917 .032 6 65 
12 363.000 .00 . . 6 64 
13 364.000 .00 . . 6 63 
14 364.000 .00 . . 6 62 
15 365.000 1.00 .902 .035 7 61 
16 365.000 .00 . . 7 60 
17 366.000 1.00 .887 .038 8 59 
18 370.000 .00 . . 8 58 
19 371.000 .00 . . 8 57 
20 372.000 .00 . . 8 56 
21 374.000 1.00 .872 .040 9 55 
22 375.000 1.00 .856 .042 10 54 
23 379.000 .00 . . 10 53 
24 381.000 1.00 . . 11 52 
25 381.000 1.00 .823 .047 12 51 
26 381.000 .00 . . 12 50 
27 383.000 .00 . . 12 49 
28 387.000 .00 . . 12 48 
29 390.000 1.00 .806 .049 13 47 
30 394.000 1.00 .789 .051 14 46 
31 400.000 1.00 . . 15 45 
32 400.000 1.00 .755 .054 16 44 
33 403.000 1.00 .738 .055 17 43 
34 408.000 1.00 .721 .057 18 42 
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35 408.000 .00 . . 18 41 
36 410.000 1.00 .703 .058 19 40 
37 419.000 1.00 . . 20 39 
38 419.000 1.00 .668 .060 21 38 
39 421.000 .00 . . 21 37 
40 441.000 .00 . . 21 36 
41 447.000 .00 . . 21 35 
42 487.000 1.00 .649 .061 22 34 
43 679.000 1.00 .630 .062 23 33 
44 680.000 1.00 .611 .063 24 32 
45 688.000 1.00 .591 .064 25 31 
46 700.000 1.00 .572 .065 26 30 
47 707.000 .00 . . 26 29 
48 713.000 1.00 .553 .066 27 28 
49 714.000 1.00 .533 .066 28 27 
50 715.000 .00 . . 28 26 
51 718.000 1.00 .512 .067 29 25 
52 728.000 1.00 .492 .067 30 24 
53 730.000 1.00 .471 .067 31 23 
54 731.000 1.00 . . 32 22 
55 731.000 1.00 .430 .067 33 21 
56 734.000 1.00 .410 .067 34 20 
57 734.000 .00 . . 34 19 
58 735.000 1.00 .388 .067 35 18 
59 740.000 1.00 .367 .067 36 17 
60 741.000 1.00 .345 .066 37 16 
61 748.000 1.00 .324 .066 38 15 
62 751.000 1.00 .302 .065 39 14 
63 754.000 .00 . . 39 13 
64 767.000 1.00 .279 .064 40 12 
65 773.000 1.00 .256 .062 41 11 
66 784.000 1.00 . . 42 10 
67 784.000 1.00 .209 .059 43 9 
68 803.000 1.00 .186 .057 44 8 
69 805.000 .00 . . 44 7 
70 970.000 1.00 .159 .055 45 6 
71 1079.000 1.00 .133 .052 46 5 
72 1087.000 1.00 .106 .048 47 4 
73 1098.000 .00 . . 47 3 
74 1156.000 1.00 .071 .043 48 2 
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75 1220.000 1.00 .035 .033 49 1 
76 1456.000 1.00 .000 .000 50 0 
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Table 8. 9 Survival Table of freedom from AAA volume increase in different IFU groups 
IFU groups: (1) IFU-2016 compliant; (2) IFU-2013 compliant (Non-compliant with IFU-2016); (3) Non-
compliant with IFU-2013 and IFU-2016. 
Survival Table 
IFUGroups Time Status 
Cumulative Proportion Surviving at 
the Time N of Cumulative 
Events 
N of Remaining 
Cases Estimate Std. Error 
1.00 1 343.000 1.00 .950 .049 1 19 
2 351.000 1.00 .900 .067 2 18 
3 351.000 .00 . . 2 17 
4 366.000 1.00 .847 .081 3 16 
5 375.000 1.00 .794 .092 4 15 
6 380.000 1.00 .741 .100 5 14 
7 387.000 .00 . . 5 13 
8 400.000 1.00 . . 6 12 
9 400.000 1.00 .627 .112 7 11 
10 403.000 1.00 .570 .116 8 10 
11 408.000 .00 . . 8 9 
12 419.000 1.00 .507 .119 9 8 
13 421.000 .00 . . 9 7 
14 487.000 1.00 .434 .122 10 6 
15 713.000 1.00 .362 .121 11 5 
16 715.000 .00 . . 11 4 
17 730.000 1.00 .271 .120 12 3 
18 760.000 .00 . . 12 2 
19 970.000 1.00 .136 .113 13 1 
20 1456.000 1.00 .000 .000 14 0 
2.00 1 325.000 .00 . . 0 34 
2 350.000 .00 . . 0 33 
3 357.000 1.00 .970 .030 1 32 
4 360.000 1.00 .939 .042 2 31 
5 365.000 1.00 .909 .050 3 30 
6 365.000 .00 . . 3 29 
7 370.000 1.00 .878 .057 4 28 
8 371.000 .00 . . 4 27 
9 374.000 1.00 .845 .064 5 26 
10 379.000 .00 . . 5 25 
11 381.000 1.00 . . 6 24 
12 381.000 1.00 .778 .074 7 23 
13 381.000 .00 . . 7 22 
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14 383.000 .00 . . 7 21 
15 394.000 1.00 .741 .080 8 20 
16 408.000 1.00 .704 .084 9 19 
17 410.000 1.00 .667 .087 10 18 
18 679.000 1.00 .629 .090 11 17 
19 700.000 1.00 .592 .092 12 16 
20 714.000 1.00 .555 .093 13 15 
21 714.000 .00 . . 13 14 
22 718.000 1.00 .516 .095 14 13 
23 728.000 1.00 .476 .095 15 12 
24 734.000 1.00 .436 .095 16 11 
25 740.000 1.00 .397 .095 17 10 
26 741.000 1.00 .357 .093 18 9 
27 748.000 1.00 .317 .091 19 8 
28 754.000 .00 . . 19 7 
29 767.000 1.00 .272 .088 20 6 
30 784.000 1.00 .227 .085 21 5 
31 805.000 .00 . . 21 4 
32 1087.000 1.00 .170 .080 22 3 
33 1098.000 .00 . . 22 2 
34 1156.000 1.00 .085 .072 23 1 
35 1220.000 1.00 .000 .000 24 0 
3.00 1 304.000 .00 . . 0 20 
2 352.000 .00 . . 0 19 
3 353.000 1.00 .947 .051 1 18 
4 363.000 .00 . . 1 17 
5 364.000 .00 . . 1 16 
6 370.000 .00 . . 1 15 
7 390.000 1.00 .884 .078 2 14 
8 410.000 1.00 .821 .094 3 13 
9 419.000 1.00 .758 .106 4 12 
10 441.000 .00 . . 4 11 
11 447.000 .00 . . 4 10 
12 680.000 1.00 .682 .120 5 9 
13 707.000 .00 . . 5 8 
14 731.000 1.00 .597 .132 6 7 
15 735.000 1.00 .512 .138 7 6 
16 737.000 .00 . . 7 5 
17 751.000 1.00 .409 .143 8 4 
18 773.000 1.00 .307 .139 9 3 
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19 784.000 1.00 .205 .125 10 2 
20 803.000 1.00 .102 .096 11 1 
21 1079.000 1.00 .000 .000 12 0 
 
Table 8. 10 Log rank results of AAA volume increase in different IFU groups 
Log Rank (Mantel – 
Cox) 
IFU-2016 Compliant IFU-2013 compliant 
(Non-compliant with 
IFU-2016) 
Non-compliant with 
IFU-2013 and IFU-
2016 
X2 P value X2 P value X2 P value  
IFU-2016 Compliant 
 
 
  0.251 0.616 0.698 0.404 
IFU-2013 compliant 
(Non-compliant with 
IFU-2016) 
0.251 0.616   0.000 0.997 
Non-compliant with 
IFU-2013 and IFU-
2016 
 
0.698 0.404 0.000 0.997   
 
Figure 8. 1 Freedom from AAA growth in different IFU groups (Cut off at SE>10%) 
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Table 8. 11 Survival Table of freedom from proximal displacement 
Survival Table 
 Time Status 
Cumulative Proportion Surviving at 
the Time N of Cumulative 
Events 
N of Remaining 
Cases Estimate Std. Error 
1 304.000 .00 . . 0 75 
2 325.000 1.00 .987 .013 1 74 
3 332.000 1.00 .973 .019 2 73 
4 350.000 .00 . . 2 72 
5 351.000 .00 . . 2 71 
6 351.000 .00 . . 2 70 
7 352.000 1.00 .959 .023 3 69 
8 357.000 1.00 .946 .026 4 68 
9 360.000 .00 . . 4 67 
10 363.000 1.00 . . 5 66 
11 363.000 1.00 .917 .032 6 65 
12 364.000 .00 . . 6 64 
13 365.000 1.00 .903 .035 7 63 
14 366.000 .00 . . 7 62 
15 370.000 1.00 . . 8 61 
16 370.000 1.00 .874 .039 9 60 
17 371.000 1.00 .859 .041 10 59 
18 374.000 1.00 .845 .043 11 58 
19 377.000 1.00 .830 .045 12 57 
20 379.000 1.00 .816 .046 13 56 
21 381.000 1.00 .801 .048 14 55 
22 381.000 .00 . . 14 54 
23 383.000 .00 . . 14 53 
24 386.000 1.00 .786 .049 15 52 
25 387.000 .00 . . 15 51 
26 390.000 1.00 .770 .051 16 50 
27 394.000 1.00 .755 .052 17 49 
28 395.000 1.00 .740 .053 18 48 
29 403.000 1.00 .724 .054 19 47 
30 408.000 .00 . . 19 46 
31 408.000 .00 . . 19 45 
32 410.000 1.00 .708 .055 20 44 
33 412.000 1.00 .692 .056 21 43 
34 421.000 .00 . . 21 42 
35 425.000 1.00 .676 .057 22 41 
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36 433.000 1.00 .659 .058 23 40 
37 441.000 1.00 .643 .059 24 39 
38 447.000 .00 . . 24 38 
39 487.000 1.00 .626 .060 25 37 
40 577.000 1.00 .609 .061 26 36 
41 679.000 1.00 .592 .061 27 35 
42 680.000 .00 . . 27 34 
43 688.000 .00 . . 27 33 
44 700.000 .00 . . 27 32 
45 710.000 1.00 .573 .062 28 31 
46 713.000 .00 . . 28 30 
47 714.000 1.00 .554 .063 29 29 
48 714.000 .00 . . 29 28 
49 715.000 .00 . . 29 27 
50 718.000 .00 . . 29 26 
51 728.000 1.00 .533 .064 30 25 
52 731.000 1.00 . . 31 24 
53 731.000 1.00 .490 .066 32 23 
54 732.000 1.00 .469 .066 33 22 
55 734.000 1.00 .448 .066 34 21 
56 735.000 .00 . . 34 20 
57 737.000 .00 . . 34 19 
58 751.000 1.00 .424 .067 35 18 
59 760.000 .00 . . 35 17 
60 767.000 .00 . . 35 16 
61 780.000 .00 . . 35 15 
62 784.000 .00 . . 35 14 
63 784.000 .00 . . 35 13 
64 867.000 1.00 .392 .069 36 12 
65 970.000 .00 . . 36 11 
66 1045.000 .00 . . 36 10 
67 1079.000 1.00 .352 .073 37 9 
68 1087.000 .00 . . 37 8 
69 1092.000 .00 . . 37 7 
70 1098.000 1.00 .302 .078 38 6 
71 1106.000 .00 . . 38 5 
72 1115.000 .00 . . 38 4 
73 1126.000 1.00 .227 .088 39 3 
74 1131.000 1.00 .151 .085 40 2 
75 1156.000 1.00 .076 .068 41 1 
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76 1176.000 1.00 .000 .000 42 0 
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Table 8. 12 Survival Table of freedom from migration 
Survival Table 
 Time Status 
Cumulative Proportion Surviving at 
the Time N of Cumulative 
Events 
N of Remaining 
Cases Estimate Std. Error 
1 304.000 .00 . . 0 75 
2 325.000 1.00 .987 .013 1 74 
3 350.000 .00 . . 1 73 
4 351.000 .00 . . 1 72 
5 351.000 .00 . . 1 71 
6 352.000 .00 . . 1 70 
7 360.000 .00 . . 1 69 
8 363.000 .00 . . 1 68 
9 364.000 .00 . . 1 67 
10 365.000 1.00 .972 .020 2 66 
11 366.000 .00 . . 2 65 
12 370.000 .00 . . 2 64 
13 371.000 .00 . . 2 63 
14 374.000 .00 . . 2 62 
15 379.000 .00 . . 2 61 
16 381.000 1.00 .956 .025 3 60 
17 381.000 .00 . . 3 59 
18 383.000 .00 . . 3 58 
19 387.000 .00 . . 3 57 
20 390.000 .00 . . 3 56 
21 394.000 .00 . . 3 55 
22 403.000 .00 . . 3 54 
23 408.000 .00 . . 3 53 
24 408.000 .00 . . 3 52 
25 410.000 .00 . . 3 51 
26 412.000 1.00 .937 .031 4 50 
27 421.000 .00 . . 4 49 
28 441.000 .00 . . 4 48 
29 447.000 .00 . . 4 47 
30 487.000 1.00 .917 .036 5 46 
31 577.000 .00 . . 5 45 
32 680.000 .00 . . 5 44 
33 688.000 .00 . . 5 43 
34 700.000 .00 . . 5 42 
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35 707.000 .00 . . 5 41 
36 710.000 .00 . . 5 40 
37 713.000 .00 . . 5 39 
38 714.000 .00 . . 5 38 
39 714.000 .00 . . 5 37 
40 715.000 .00 . . 5 36 
41 718.000 .00 . . 5 35 
42 728.000 .00 . . 5 34 
43 731.000 .00 . . 5 33 
44 732.000 .00 . . 5 32 
45 734.000 .00 . . 5 31 
46 735.000 .00 . . 5 30 
47 737.000 .00 . . 5 29 
48 740.000 1.00 .886 .047 6 28 
49 751.000 1.00 .854 .055 7 27 
50 760.000 1.00 .822 .061 8 26 
51 760.000 .00 . . 8 25 
52 767.000 .00 . . 8 24 
53 780.000 .00 . . 8 23 
54 783.000 1.00 .787 .068 9 22 
55 784.000 .00 . . 9 21 
56 784.000 .00 . . 9 20 
57 803.000 1.00 .747 .075 10 19 
58 805.000 .00 . . 10 18 
59 867.000 1.00 .706 .082 11 17 
60 970.000 .00 . . 11 16 
61 1045.000 .00 . . 11 15 
62 1065.000 1.00 .659 .089 12 14 
63 1078.000 .00 . . 12 13 
64 1087.000 .00 . . 12 12 
65 1091.000 .00 . . 12 11 
66 1092.000 .00 . . 12 10 
67 1098.000 .00 . . 12 9 
68 1106.000 .00 . . 12 8 
69 1115.000 .00 . . 12 7 
70 1176.000 .00 . . 12 6 
71 1334.000 1.00 .549 .125 13 5 
72 1443.000 1.00 .439 .140 14 4 
73 1456.000 1.00 .329 .142 15 3 
74 1457.000 1.00 .220 .130 16 2 
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75 1465.000 .00 . . 16 1 
76 1490.000 .00 . . 16 0 
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Table 8. 13 Survival Table of freedom from proximal displacement in different IFU groups 
 
IFU groups: (1) IFU-2016 compliant; (2) IFU-2013 compliant (Non-compliant with IFU-2016); (3) Non-
compliant with IFU-2013 and IFU-2016. 
Survival Table 
IFUGROUPS Time Status 
Cumulative Proportion Surviving at 
the Time N of Cumulative 
Events 
N of Remaining 
Cases Estimate Std. Error 
1.00 1 351.000 .00 . . 0 19 
2 351.000 .00 . . 0 18 
3 366.000 .00 . . 0 17 
4 387.000 .00 . . 0 16 
5 403.000 1.00 .938 .061 1 15 
6 408.000 .00 . . 1 14 
7 421.000 .00 . . 1 13 
8 425.000 1.00 .865 .089 2 12 
9 487.000 1.00 .793 .107 3 11 
10 688.000 .00 . . 3 10 
11 710.000 1.00 .714 .122 4 9 
12 713.000 .00 . . 4 8 
13 715.000 .00 . . 4 7 
14 760.000 .00 . . 4 6 
15 970.000 .00 . . 4 5 
16 1092.000 .00 . . 4 4 
17 1106.000 .00 . . 4 3 
18 1115.000 .00 . . 4 2 
19 1126.000 1.00 .357 .260 5 1 
20 1176.000 1.00 .000 .000 6 0 
2.00 1 325.000 1.00 .971 .028 1 34 
2 350.000 .00 . . 1 33 
3 357.000 1.00 .942 .040 2 32 
4 360.000 .00 . . 2 31 
5 363.000 1.00 .912 .049 3 30 
6 365.000 1.00 .881 .056 4 29 
7 370.000 1.00 .851 .062 5 28 
8 371.000 1.00 .820 .066 6 27 
9 374.000 1.00 .790 .071 7 26 
10 379.000 1.00 .760 .074 8 25 
11 381.000 1.00 .729 .077 9 24 
12 381.000 .00 . . 9 23 
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13 383.000 .00 . . 9 22 
14 386.000 1.00 .696 .080 10 21 
15 394.000 1.00 .663 .083 11 20 
16 395.000 1.00 .630 .085 12 19 
17 408.000 .00 . . 12 18 
18 412.000 1.00 .595 .088 13 17 
19 433.000 1.00 .560 .089 14 16 
20 577.000 1.00 .525 .090 15 15 
21 679.000 1.00 .490 .091 16 14 
22 700.000 .00 . . 16 13 
23 714.000 1.00 .452 .091 17 12 
24 714.000 .00 . . 17 11 
25 718.000 .00 . . 17 10 
26 728.000 1.00 .407 .093 18 9 
27 731.000 1.00 .362 .093 19 8 
28 734.000 1.00 .317 .091 20 7 
29 767.000 .00 . . 20 6 
30 784.000 .00 . . 20 5 
31 867.000 1.00 .253 .093 21 4 
32 1087.000 .00 . . 21 3 
33 1098.000 1.00 .169 .092 22 2 
34 1131.000 1.00 .084 .076 23 1 
35 1156.000 1.00 .000 .000 24 0 
3.00 1 304.000 .00 . . 0 20 
2 332.000 1.00 .950 .049 1 19 
3 352.000 1.00 .900 .067 2 18 
4 363.000 1.00 .850 .080 3 17 
5 364.000 .00 . . 3 16 
6 370.000 1.00 .797 .091 4 15 
7 377.000 1.00 .744 .099 5 14 
8 390.000 1.00 .691 .105 6 13 
9 410.000 1.00 .638 .110 7 12 
10 441.000 1.00 .584 .113 8 11 
11 447.000 .00 . . 8 10 
12 680.000 .00 . . 8 9 
13 731.000 1.00 .519 .117 9 8 
14 732.000 1.00 .455 .119 10 7 
15 735.000 .00 . . 10 6 
16 737.000 .00 . . 10 5 
17 751.000 1.00 .364 .125 11 4 
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18 780.000 .00 . . 11 3 
19 784.000 .00 . . 11 2 
20 1045.000 .00 . . 11 1 
21 1079.000 1.00 .000 .000 12 0 
 
 
Table 8. 14 Log rank results of proximal displacement in different IFU groups 
Log Rank (Mantel – 
Cox) 
IFU-2016 Compliant IFU-2013 compliant 
(Non-compliant with 
IFU-2016) 
Non-compliant with 
IFU-2013 and IFU-
2016 
X2 P value X2 P value X2 P value  
IFU-2016 Compliant 
 
 
  7.592 0. 006 5.350 0.021 
IFU-2013 compliant 
(Non-compliant with 
IFU-2016) 
7.592 0.006   0.081 0.775 
Non-compliant with 
IFU-2013 and IFU-
2016 
 
5.350 0.021 .081 0.775   
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Figure 8. 2 Freedom from proximal displacement in different IFU groups (Cut off at SE>10%) 
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Table 8. 15 Survival Table of freedom from migration in different IFU groups 
Survival Table 
IFUGROUPS Time Status 
Cumulative Proportion Surviving at 
the Time N of Cumulative 
Events 
N of Remaining 
Cases Estimate Std. Error 
1.00 1 351.000 .00 . . 0 19 
2 351.000 .00 . . 0 18 
3 366.000 .00 . . 0 17 
4 387.000 .00 . . 0 16 
5 403.000 .00 . . 0 15 
6 408.000 .00 . . 0 14 
7 421.000 .00 . . 0 13 
8 487.000 1.00 .923 .074 1 12 
9 688.000 .00 . . 1 11 
10 710.000 .00 . . 1 10 
11 713.000 .00 . . 1 9 
12 714.000 .00 . . 1 8 
13 715.000 .00 . . 1 7 
14 760.000 .00 . . 1 6 
15 970.000 .00 . . 1 5 
16 1092.000 .00 . . 1 4 
17 1106.000 .00 . . 1 3 
18 1115.000 .00 . . 1 2 
19 1176.000 .00 . . 1 1 
20 1456.000 1.00 .000 .000 2 0 
2.00 1 325.000 1.00 .971 .028 1 34 
2 350.000 .00 . . 1 33 
3 360.000 .00 . . 1 32 
4 365.000 1.00 .941 .040 2 31 
5 371.000 .00 . . 2 30 
6 374.000 .00 . . 2 29 
7 379.000 .00 . . 2 28 
8 381.000 1.00 .907 .051 3 27 
9 381.000 .00 . . 3 26 
10 383.000 .00 . . 3 25 
11 394.000 .00 . . 3 24 
12 408.000 .00 . . 3 23 
13 412.000 1.00 .868 .062 4 22 
14 577.000 .00 . . 4 21 
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15 700.000 .00 . . 4 20 
16 714.000 .00 . . 4 19 
17 718.000 .00 . . 4 18 
18 728.000 .00 . . 4 17 
19 731.000 .00 . . 4 16 
20 734.000 .00 . . 4 15 
21 740.000 1.00 .810 .081 5 14 
22 760.000 1.00 .752 .093 6 13 
23 767.000 .00 . . 6 12 
24 783.000 1.00 .690 .105 7 11 
25 784.000 .00 . . 7 10 
26 805.000 .00 . . 7 9 
27 867.000 1.00 .613 .118 8 8 
28 1065.000 1.00 .536 .125 9 7 
29 1078.000 .00 . . 9 6 
30 1087.000 .00 . . 9 5 
31 1098.000 .00 . . 9 4 
32 1334.000 1.00 .402 .149 10 3 
33 1443.000 1.00 .268 .148 11 2 
34 1465.000 .00 . . 11 1 
35 1490.000 .00 . . 11 0 
3.00 1 304.000 .00 . . 0 20 
2 352.000 .00 . . 0 19 
3 363.000 .00 . . 0 18 
4 364.000 .00 . . 0 17 
5 370.000 .00 . . 0 16 
6 390.000 .00 . . 0 15 
7 410.000 .00 . . 0 14 
8 441.000 .00 . . 0 13 
9 447.000 .00 . . 0 12 
10 680.000 .00 . . 0 11 
11 707.000 .00 . . 0 10 
12 732.000 .00 . . 0 9 
13 735.000 .00 . . 0 8 
14 737.000 .00 . . 0 7 
15 751.000 1.00 .857 .132 1 6 
16 780.000 .00 . . 1 5 
17 784.000 .00 . . 1 4 
18 803.000 1.00 .643 .210 2 3 
19 1045.000 .00 . . 2 2 
P a g e  | 127 
 
 
20 1091.000 .00 . . 2 1 
21 1457.000 1.00 .000 .000 3 0 
 
 
Table 8. 16 Log rank results of migration in different IFU groups 
Log Rank (Mantel – 
Cox) 
IFU-2016 Compliant IFU-2013 compliant 
(Non-compliant with 
IFU-2016) 
Non-compliant with 
IFU-2013 and IFU-
2016 
X2 P value X2 P value X2 P value  
IFU-2016 Compliant 
 
 
  2.011 0.156 0.015 0.904 
IFU-2013 compliant 
(Non-compliant with 
IFU-2016) 
2.011 0.156   0.510 0.475 
Non-compliant with 
IFU-2013 and IFU-
2016 
 
0.015 0.904 0.510 0.475   
 
 
Figure 8. 3 Freedom from migration in different IFU groups (Cut off at SE>10%) 
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8.4. Diameter vs Volume  
Table 8. 17 Pearson correlation of AAA volume x AAA maximum diameter at each time point 
Time  Pearson correlation  P value  
One month  0.837 0.000 
One year 0.927 0.000 
Two years 0.872 0.000 
Three years 0.849 0.000 
Four years 0.878 0.009 
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Figure 8. 4 Scatter plot of AAA volume x AAA maximum diameter at each time point 
 
 
 
 
 
 
 
P a g e  | 130 
 
 
 
8.5. Linear Mixed Model  
Step 1: Unconditional Mean Model (Model 1) 
 
Table 8. 18 Model 1: Information Criteriaa 
-2 Log Likelihood 2334.620 
Akaike's Information Criterion 
(AIC) 
2340.620 
Hurvich and Tsai's Criterion 
(AICC) 
2340.731 
Bozdogan's Criterion (CAIC) 2353.815 
Schwarz's Bayesian Criterion 
(BIC) 
2350.815 
The information criteria are displayed in 
smaller-is-better form. 
a. Dependent Variable: AAA volume. 
 
Table 8. 19 Model 1: Estimates of Fixed Effectsa 
Parameter Estimate Std. Error df t Sig. 
95% Confidence Interval 
Lower Bound Upper Bound 
Intercept 216.154661 12.005293 75.327 18.005 .000 192.240593 240.068729 
a. Dependent Variable: AAA volume. 
 
 
Table 8. 20 Model 1: Estimates of Covariance Parametersa 
Parameter Estimate Std. Error Wald Z Sig. 
95% Confidence Interval 
Lower Bound Upper Bound 
Residual 581.363271 68.436166 8.495 .000 461.579969 732.231197 
Intercept [subject = 
id] 
Variance 10735.107612 1785.129466 6.014 .000 7749.273978 14871.397729 
a. Dependent Variable: AAA volume. 
 
Intraclass correlation coefficient (ICC) = 10735/(10735+581) = 0.94866 
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Step 2: Unconditional Linear Growth Curve Model (Model 2) 
Table 8. 21 Model 2: Information Criteriaa 
-2 Log Likelihood 2248.888 
Akaike's Information Criterion 
(AIC) 
2260.888 
Hurvich and Tsai's Criterion 
(AICC) 
2261.280 
Bozdogan's Criterion (CAIC) 2287.277 
Schwarz's Bayesian Criterion 
(BIC) 
2281.277 
The information criteria are displayed in 
smaller-is-better form. 
a. Dependent Variable: AAA volume. 
 
 
Table 8. 22 Model 2: Estimates of Fixed Effectsa 
 
Parameter Estimate Std. Error df t Sig. 
95% Confidence Interval 
Lower Bound Upper Bound 
Intercept 196.201040 13.462080 72.237 14.574 .000 169.366379 223.035701 
Time 9.366164 2.184228 45.321 4.288 .000 4.967763 13.764565 
a. Dependent Variable: AAA volume. 
 
 
Table 8. 23 Model 2: Estimates of Covariance Parametersa 
Parameter Estimate Std. Error Wald Z Sig. 
95% Confidence Interval 
Lower Bound Upper Bound 
Residual 175.074763 31.541330 5.551 .000 122.990554 249.215666 
Intercept + Time 
[subject = id] 
UN (1,1) 13316.948237 2296.737156 5.798 .000 9497.304021 18672.784399 
UN (2,1) -921.364319 364.530602 -2.528 .011 -1635.831169 -206.897468 
UN (2,2) 235.647320 76.285387 3.089 .002 124.941187 444.446389 
a. Dependent Variable: AAA volume. 
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Step 3: Quadratic Growth Curve Model (Higher-Order Change Trajectories) (Model 3) 
 
Table 8. 24 Model 3: Information Criteriaa 
-2 Log Likelihood 2223.140 
Akaike's Information Criterion 
(AIC) 
2237.140 
Hurvich and Tsai's Criterion 
(AICC) 
2237.666 
Bozdogan's Criterion (CAIC) 2267.927 
Schwarz's Bayesian Criterion 
(BIC) 
2260.927 
The information criteria are displayed in 
smaller-is-better form. 
a. Dependent Variable: AAA volume. 
 
 
Table 8. 25 Model 3: Estimates of Fixed Effectsa 
Parameter Estimate Std. Error df t Sig. 
95% Confidence Interval 
Lower Bound Upper Bound 
Intercept 213.461511 13.678460 81.167 15.606 .000 186.246516 240.676505 
Time -9.849463 4.031823 128.035 -2.443 .016 -17.827093 -1.871832 
Time2 4.531265 .810940 83.694 5.588 .000 2.918537 6.143993 
a. Dependent Variable: AAA volume. 
 
 
Table 8. 26 Model 3: Estimates of Covariance Parametersa 
Parameter Estimate Std. Error Wald Z Sig. 
95% Confidence Interval 
Lower Bound Upper Bound 
Residual 119.646740 21.685282 5.517 .000 83.873641 170.677489 
Intercept + 
Time [subject = 
id] 
UN (1,1) 13206.454365 2239.494636 5.897 .000 9472.030328 18413.205074 
UN (2,1) -918.131730 339.841552 -2.702 .007 -1584.208933 -252.054528 
UN (2,2) 274.366325 72.782949 3.770 .000 163.127434 461.460578 
a. Dependent Variable: AAA volume. 
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Step 4: Cubic Growth Curve Model (Higher-Order Change Trajectories) (Model 4) 
 
Table 8. 27 Model 4: Information Criteriaa 
-2 Log Likelihood 2217.347 
Akaike's Information Criterion 
(AIC) 
2233.347 
Hurvich and Tsai's Criterion 
(AICC) 
2234.026 
Bozdogan's Criterion (CAIC) 2268.532 
Schwarz's Bayesian Criterion 
(BIC) 
2260.532 
The information criteria are displayed in 
smaller-is-better form. 
a. Dependent Variable: AAA volume. 
 
 
Table 8. 28 Model 4: Estimates of Fixed Effectsa 
Parameter Estimate Std. Error df t Sig. 
95% Confidence Interval 
Lower Bound Upper Bound 
Intercept 231.468638 15.458210 122.334 14.974 .000 200.868405 262.068871 
Time -37.781041 12.011795 76.641 -3.145 .002 -61.701368 -13.860715 
Time2 16.557427 4.955564 73.041 3.341 .001 6.681095 26.433759 
Time3 -1.475189 .601337 70.988 -2.453 .017 -2.674224 -.276153 
a. Dependent Variable: AAA volume. 
 
 
 
Table 8. 29 Model 4: Estimates of Covariance Parametersa 
Parameter Estimate Std. Error Wald Z Sig. 
95% Confidence Interval 
Lower Bound Upper Bound 
Residual 110.695619 20.184776 5.484 .000 77.431596 158.249610 
Intercept + Time  
[subject = id] 
UN (1,1) 13154.34928
6 
2224.309147 5.914 .000 9443.589433 18323.21347
4 
UN (2,1) -895.317726 333.179518 -2.687 .007 -1548.337581 -242.297872 
UN (2,2) 276.543132 71.687814 3.858 .000 166.382376 459.640652 
a. Dependent Variable: AAA volume. 
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Step 5: Adding Potential Predictors (Model 5) 
 
Table 8. 30 Model 5: Information Criteriaa 
-2 Log Likelihood 2197.492 
Akaike's Information Criterion 
(AIC) 
2227.492 
Hurvich and Tsai's Criterion 
(AICC) 
2229.834 
Bozdogan's Criterion (CAIC) 2293.465 
Schwarz's Bayesian Criterion 
(BIC) 
2278.465 
The information criteria are displayed in 
smaller-is-better form. 
a. Dependent Variable: AAA volume. 
 
 
Table 8. 31 Model 5: Estimates of Fixed Effectsa 
Parameter Estimate Std. Error df t Sig. 
95% Confidence Interval 
Lower Bound Upper Bound 
Intercept 432.014311 153.460800 73.995 2.815 .006 126.236656 737.791966 
Time -37.281785 11.950914 78.485 -3.120 .003 -61.071911 -13.491659 
Time2 16.342388 4.927925 74.742 3.316 .001 6.524903 26.159873 
Time3 -1.454499 .598010 72.646 -2.432 .017 -2.646430 -.262568 
Age -1.668147 1.414615 73.322 -1.179 .242 -4.487261 1.150968 
Neck Angle -1.136889 .648688 73.010 -1.753 .084 -2.429719 .155941 
Neck Diameter 5.651240 2.019639 72.421 2.798 .007 1.625564 9.676916 
Neck Length -.906380 .876127 71.203 -1.035 .304 -2.653242 .840482 
ratio of 
maximum AAA 
diameter to 
maximum AAA 
lumen 
diameter 
-27.394479 20.181770 71.098 -1.357 .179 -67.634826 12.845869 
Proximal 
displacement  
-7.427173 24.602246 72.733 -.302 .764 -56.462416 41.608070 
Migration 62.183027 29.099272 72.198 2.137 .036 4.177411 120.188642 
a. Dependent Variable: AAA volume. 
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Table 8. 32 Model 5: Estimates of Covariance Parametersa 
Parameter Estimate Std. Error Wald Z Sig. 
95% Confidence Interval 
Lower Bound 
Upper 
Bound 
Residual 109.529487 19.729090 5.552 .000 76.949830 155.902987 
Intercept + Time 
[subject = id] 
UN (1,1) 11143.426737 1898.922972 5.868 .000 7979.352937 15562.15904
1 
UN (2,1) -981.037898 314.165606 -3.123 .002 -1596.791171 -365.284624 
UN (2,2) 283.459691 71.987921 3.938 .000 172.313249 466.298424 
a. Dependent Variable: AAA volume. 
 
 
